Document:

EX-10.8

 Exhibit 10.8 

SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED. THESE REDACTED TERMS HAVE BEEN
MARKED IN THIS EXHIBIT WITH THREE ASTERISKS [***]. AN UNREDACTED VERSION OF THIS EXHIBIT HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

REATA PHARMACEUTICALS, INC. - DARTMOUTH EXCLUSIVE LICENSE AGREEMENT 

This Agreement, effective this 16th day of December 2009, between 

TRUSTEES OF DARTMOUTH COLLEGE, a non-profit educational and research institution existing under the laws of the State of New Hampshire, and
being located at Hanover, New Hampshire 03755, hereinafter called Dartmouth, 
 and 

REATA PHARMACEUTICALS. INC., a corporation of the State of Texas, with a principal place of business at 2801 Gateway Drive, Suite 150, Irving,
Texas 75063; hereinafter called Company or Reata. 
 WHEREAS, [***] are named as inventors in certain United States and foreign
patent applications concerning the use of CDDO-Me (a.k.a. RTA 402, a.k.a. bardoxolone methyl) and related synthetic triterpenoids in the treatment of renal disease, cardiovascular disease, diabetes, and related disorders; and 

WHEREAS, Dartmouth represents that it has the right to grant the licenses granted in this agreement; and 

WHEREAS, Company wishes to obtain a license under the terms and conditions hereinafter set forth, and to use its expertise and resources to
manufacture and market the technology; 
 NOW THEREFORE, in consideration of the premises and the faithful performance of the covenants
herein contained, IT IS AGREED: 
 ARTICLE I. Definitions 

Section 1.01 Dartmouth Know-How. “Dartmouth Know-How” shall mean any ideas, methods, characterization and techniques
developed by Dartmouth Inventors at Dartmouth before the Effective Date, which are necessary for practicing Dartmouth Patent Rights. 

Section 1.02 Dartmouth Patent Rights. “Dartmouth Patent Rights” shall mean Dartmouth rights in United States provisional
patent applications [***] and [***] and United States Patent Application Serial [***], filed on [***], and any United States or Foreign Patents issuing therefrom, and any continuations, continuations-· in-part, divisions, reissues,
reexaminations or extensions thereof. Company and Dartmouth are the joint assignees and owners of all such Patents and Patent Applications. 

Section 1.03 Licensed Products. “Licensed Products” shall mean any products or processes covered by or made, in whole or
in part, by the use of Dartmouth Patent Rights or by the use of Dartmouth Know-How 
 Section 1.04 Field. The “Field”
of this Agreement shall mean any and all aspects of the inventions set forth for the first time in the Dartmouth Patent Rights, including but not limited to United States Patent Application [***]. 

Section 1.05 Territory. The “Territory” shall mean the world. 

Section 1.06 Affiliate. “Affiliate” means any business entity more than 50% owned by LICENSEE, any business entity that
owns more than 50% of LICENSEE, or any business entity that is more than 50% owned by a business entity that owns more than 50% of LICENSEE. 

  
 pg. 1 

 Section 1.07 Agreement. “Agreement” shall mean this License Agreement. 

Section 1.08 Net Sales. “Net Sales” shall mean the gross billing price Company, its subsidiaries and sublicensees charge
to their customers for Licensed Products, less credits, sales, use, occupation and excise taxes, and transportation, discounts, returns and allowances in lieu of returns. 

Section 1.09 Effective Date. “Effective Date” shall mean the date first written above and shall be the Effective Date of
this Agreement. 
 Section 1.10 License Year. The “First License Year” shall mean the period commencing on the
Effective Date and ending December 31, 2009. The second and all subsequent “License Years” shall commence on January 1 and end on December 31 of each year. 

Section 1.11 Calendar Quarter. “Calendar Quarter” shall mean the periods ending on
March 31, June 30, September 30 and December 31 of each year. 
 Section 1.12 Valid Claim.
“Valid Claim” shall mean an issued or pending claim under the Dartmouth Patent Rights in any country, which, but for the licenses granted herein, would be infringed by use of a Licensed Product in an approved or developmental indication.

 Section 1.13 Original Dartmouth Patents. “Original Dartmouth Patents” shall mean [***]; [***];[***]; [***]; and all
divisionals, continuations, continuations-in-part, and foreign equivalents. 
 ARTICLE II. Grant 

Section 2.01 License Grant. Dartmouth hereby grants to Company and its Subsidiaries an exclusive, royalty-bearing license
under Dartmouth Know-How and Dartmouth Patent Rights to make, have made, use, and/or sell Licensed Products in the Field in the Territory. Notwithstanding the foregoing, Dartmouth expressly reserves a non-transferable royalty-free right to
use, for educational and non-clinical research purposes only, the Dartmouth Patent Rights and Dartmouth Know-How in the Field itself, including use by its faculty, staff and researchers. 

Section 2.02 Sublicenses. Company shall have the right to grant sublicenses to third parties under Dartmouth Know-How and Patent
Rights to make, have made, use and sell the Licensed Products. All such sublicenses shall be in writing and expressly subject to the terms of this Agreement. Company agrees to be responsible for the performance hereunder by its sublicensees.
Dartmouth shall have the right to review such sublicenses to assure conformity with this Section. Upon termination of this Agreement, any such sublicenses will revert directly to Dartmouth. 

Section 2.03 Patents. Company shall be responsible for all expenses in connection with the preparation, filing, prosecution and
maintenance of Dartmouth Patent Rights. Company and Dartmouth shall continue using the firm of Fulbright & Jaworski L.L.P., or a successor firm chosen by Company and reasonably acceptable to Dartmouth, for the preparation, filing,
prosecution and maintenance of Dartmouth Patent Rights. Dartmouth shall continue to exercise its right to review the documents related thereto with the counsel of its own and provide recommendations. Costs of such consultations shall be reimbursed
to Dartmouth by the Company. As of December 9, 2009 such costs amounted to $[***]. If Company chooses 

  
 pg. 2 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 
to discontinue prosecution or maintenance of any United States Patent or Patent Application, which is a subject of Dartmouth Patent Rights, it will so inform Dartmouth within a reasonable time
before implementation of such decision. Dartmouth then shall have the right to prosecute or maintain such Patent or Patent Application on its own and at its own expense, in which case the license to Company under such Patent or Patent Application
will terminate. COMPANY shall notify Dartmouth by at least three (3) months before a National Phase deadline whether it will support the filing of patent applications in particular foreign territories. If COMPANY decides not to support the
filing or maintaining foreign applications, Dartmouth reserves the right to file or maintain such applications on its own, in which case the license to COMPANY in the particular territory will terminate. 

ARTICLE III. 

Disclosure of Invention, Confidentiality and Representations 

Section 3.01 Disclosure of Invention. Dartmouth agrees promptly after the Effective Date of this Agreement to deliver and to
disclose to duly authorized representatives of Company, all proprietary technical data, methods, processes, including the technology, and other information and specifications relating to Dartmouth Know-How. 

Section 3.02 Mutual Confidentiality. Company and Dartmouth realize that some information received by one party from the other
pursuant to this Agreement shall be confidential. It is therefore agreed that any information received by one party from the other, and clearly designated in writing as “CONFIDENTIAL” at the time of transfer, shall not be disclosed
by the receiving party to any third party and shall not be used by the receiving party for purposes other than those contemplated by this Agreement for a period of three (3) years from the termination of the Agreement, unless or until—

 (a) said information shall become known to third parties not under any obligation of confidentiality to the disclosing party, or shall
become publicly known through no fault of the receiving party, or 
 (b) said information was already in the receiving party’s
possession prior to the disclosure of said information to the receiving party, except in cases when the information has been covered by a preexisting Confidentiality Agreement. or 

(c) said information shall be subsequently disclosed to the receiving party by a third party not under any obligation of confidentiality to
the disclosing party, or 
 (d) said information is approved for disclosure by prior written consent of the disclosing party, or 

(e) said information is required to be disclosed by court order or govern- mental law or regulation,
provided that the receiving party gives the disclosing party prompt notice of any such requirement and cooperates with the disclosing party in attempting to limit such disclosure. 

Section 3.03 Corporate Action. Dartmouth and Company each represent and warrant to the other party that they have full power and
authority to enter into this Agreement and carry out the transactions contemplated hereby, and that all necessary corporate action had been duly taken in this regard. 

  
 pg. 3 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 ARTICLE IV. Due Diligence 

Section 4.01 Milestones. Company has represented to Dartmouth, to induce Dartmouth to issue this license, that it will commit
itself to a diligent program of exploiting the Licensed Products so that public utilization will result therefrom. Company agrees to use commercially reasonable efforts to develop, commercialize, and market Licensed Products, including by targeting
the following developmental milestones: 
 (a) [***] 
 (b)
[***] 
 (c) [***]; 
 ARTICLE V. Payments,
Records and Reports 
 Section 5.01 Payments. For the rights and privileges granted under this license, Company shall
pay to Dartmouth 
 (a) a non-refundable, non-creditable, one-time license access fee of $[***] due upon execution of this Agreement; and

 (b) annual license maintenance fee of $[***] due upon each anniversary of the Agreement; and 

(c) [***] percent ([***] %) of any consideration, received from an infringement settlement, less litigation expenditures and payments of
portions due to sublicensees (if any) from the settlement, as described in Section 8.01, and from each sublicense, except running royalty on the sale of Licensed Products (e.g., license issue fees, license maintenance fees, lump sum payments in
lieu of royalty payments, stocks, etc.) received from each sublicensee of Company for the grant of a sublicense. It is agreed that R&D payments from sublicensees to Company shall not be the subject to this Subsection 5.01(c); and 

(d) for the achievement of the following milestones for each indication in the first territory a non-refundable, non-creditable milestone
payment as follows: 
  

									
	 [***]
	  	$	[	***] 	 			
			
	 [***]
	  	$	[	***] 	 			
			
	 [***]
	  				 	$	[	***] 

 Company shall notify Dartmouth within 30 days of the achievement of each milestone event, and payment of the associated fee
shall be due within 30 days of milestone achievement. 
 (e) [***]: 

 

					
	 [***]
	  	$	[	***] 
	 [***]
	  	$	[	***] 

  
 pg. 4 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 (f) Upon expiration of the Original Dartmouth Patents in any territory or termination of
Exclusive Patent License Agreement among The University of Texas; M.D. Anderson Cancer Center Dartmouth College and Reata Discovery, Inc., whichever is sooner, Reata shall pay to Dartmouth a royalty of [***] % of Net Sales of Licensed Products in
that territory, so long as the sale of any Reata product in that territory is covered by one or more Valid Claims in any of the Dartmouth Patent Rights; and 

(g) In addition to any royalties on sales of Licensed Products payable to Dartmouth under this or any other agreement, Company will pay the
following super-royalty based on the achievement of sales milestones of Licensed Products worldwide, as follows: 
 $[***] for achieving
$[***] in aggregate Net Sales 
 $[***] for achieving $[***] in aggregate Net Sales 

$[***] for achieving $[***] in aggregate Net Sales 

$[***] for achieving $[***] in aggregate Net Sales 

$[***] for achieving $[***] in aggregate Net Sales 

Section 5.02 Reports. Company shall render to Dartmouth: 

(a) Beginning with the date of first commercial sale of a Licensed Product in any country, within sixty (60) days after the end of each
Calendar Quarter a written account of all quantities of Licensed Products subject to royalty hereunder sold by Company, any Affiliate, and any sublicensee during such Calendar Quarter, the calculation of royalty thereon, and sufficient data for
Dartmouth to verify the calculation, including gross sales and allowable deductions to derive to Net Sales figures, and shall simultaneously pay in United States dollars to Dartmouth the royalty due with respect to such sales. Conversion of foreign
currency to U.S. dollars shall be made at the conversion rate existing in the United States on the date of royalty payments by Company. Such report shall be certified as correct by an officer of Company. If, after the date of first commercial sale,
no Licensed Products subject to royalty hereunder have been sold by Company, its Subsidiaries and its sublicensees during any such quarter, Company shall so report in writing to Dartmouth within sixty (60) days after the end of said quarter.
Prior to the date of first commercial sale of a Licensed Product, no royalty reports will be required. If royalties for any License Year do not equal or exceed the minimum royalties established in Section 4.03, Company shall include the balance
of the minimum royalty with the payment for the Calendar Quarter ending December 31. Late payments shall be subject to an interest charge of [***] (%) per month. 

(b) within sixty (60) days after the close of each License Year written annual reports which shall include but not limited to: reports of
progress on research and development, regulatory approvals, manufacturing, sublicensing, marketing and sales during preceding twelve (12) months as well as plans for coming year. Company shall also provide any reasonable additional data
Dartmouth requires to evaluate Company’s performance. 
 (c) within sixty (60) days of occurrence, report of the date of first
sale of Licensed Products in each country. 
 Section 5.03 Books of Accounts. Company, its Subsidiaries and sublicensees shall
keep full, true and accurate books of accounts and other records containing all particulars which may be necessary for the purpose of ascertaining and verifying the royalties payable to Dartmouth by Company hereunder. Upon Dartmouth’s request,
Company, its Subsidiaries and sublicensees shall permit an independent Certified Accountant selected by Dartmouth (except one to whom Company has some reasonable objection), to 

  
 pg. 5 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 
periodically have access during ordinary business hours to such records of Company, its Subsidiaries and sublicensees as may be necessary to determine, for any quarter ending not more than three
(3) years prior to the date of such request, the correctness of any report and/or payment made under this Agreement. In the event that any such inspection shows an underreporting and underpayment in excess of [***] percent ([***]%) for any
twelve (12) month period, then Company shall pay the cost of such examination. 
 ARTICLE VI. Technical Assistance and Commercial
Development 
 Section 6.01 Technical Assistance. Throughout the term of the Agreement, Dartmouth agrees to permit
Company and its designees to consult with its employees and agents regarding developments and enhancements made subsequent to the Effective Date relating to the Licensed Products, at such times and places as may be mutually agreed upon; provided
that Company agrees to make suitable arrangements with, and to compensate the Dartmouth employees and agents for such consultation. 

Section 6.02 Commercial Development. During the term of this Agreement, Company agrees to use commercially reasonable efforts to
effectively manufacture and market Licensed Products. Such efforts will include sublicensing, development of promotional literature, mailings, and journal advertisements. 

Section 6.03 Name. Company shall not use and shall not permit to be used by any other person or entity the name of Dartmouth nor
any adaptation thereof, or the name of Dartmouth’s employees, in any advertising, promotional or sales literature, or for any other purpose without prior written permission of Dartmouth, except that Company may state that it is licensed by
Dartmouth under Dartmouth Know-How and Patent Rights. 
 ARTICLE VII. Indemnity, Insurance, Disclaimers 

Section 7.01 Indemnity. Company shall defend and indemnify and hold Dartmouth and its trustees, officers, agents and employees
(the “lndemnitees”) harmless from any judgements and other liabilities based upon claims or causes of action against Dartmouth or its employees which arise out of alleged negligence in the development, manufacture or sale of Licensed
Products by Company, its Subsidiaries, and sublicensees, or from the use by the end users of Licensed Products, except to the extent that such judgements or liabilities arise in whole or in part from the gross negligence or willful misconduct of
Dartmouth or its employees, provided that Dartmouth promptly notifies Company of any such claim coming to its attention and that it cooperates with Company in the defense of such claim. If any such claims or causes of action are made, Dartmouth
shall be defended by counsel to Company, subject to Dartmouth’s approval, which shall not be unreasonably withheld. Dartmouth reserves the right to be represented by its own counsel at its own expense. 

Section 7.02 Insurance. At such time as any product, process, service relating to, or developed pursuant to, this Agreement is
being commercially distributed or sold (other than for the purpose of obtaining regulatory approvals) by Company or by a sublicensee, Affiliate or agent of Company, Company shall at its sole cost and expense, procure and maintain comprehensive
general liability insurance in amounts not less than $[***] per incident and naming the indemnitees as additional insureds. Such comprehensive general liability insurance shall provide (i) product liability coverage and (ii) broad form
contractual liability coverage for Company’s indemnification under this Agreement. If Company elects to self-insure all or part of the limits described above (including deductibles or retentions which are in excess of $[***] annual aggregate)
such self-insurance program must be acceptable to Dartmouth and Dartmouth Risk Manager. Such insurance will be considered primary as to any other valid and collectible insurance, but only as to acts of the named insured. The minimum amounts of
insurance coverage required shall not be construed to create a limit of Company’s liability with respect to its indemnification under this Agreement. 

  
 pg. 6 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Company shall provide Dartmouth with written evidence of such insurance upon request of Dartmouth. Company shall
provide Dartmouth with written notice at least fifteen (15) days prior to the cancellation, non-renewal or material change in such insurance; if Company does not obtain replacement insurance providing comparable coverage within such fifteen
(15) day period, Dartmouth shall have the right to terminate this Agreement effective at the end of such fifteen (15) day period without notice or any additional waiting periods. 

Company shall maintain such comprehensive general liability insurance beyond the expiration or termination of this Agreement during (I) the period that
any product, process, or service, relating to, or developed pursuant to, this Agreement is being commercially distributed or sold by Company or by a sublicensee, Affiliate or agent of Company and (ii) a reasonable period after the period
referred to in (i) above which in no event shall be less than fifteen (15) years. 
 Section 7.03 Disclaimer. Nothing
contained in this Agreement shall be construed as: 
 (a) a warranty or representation by Dartmouth as to the validity or scope of any
Patent Rights; 
 (b) a warranty or representation that any Licensed Products manufactured, used or sold will be free from infringement of
patents, copyrights, or rights of third parties, except that Dartmouth represents that it has no knowledge of any existing issued patents or copyrights which might be infringed; 

(c) except as provided in Section 7.01, an agreement to defend against actions or suits of any nature brought by any third parties. 

DARTMOUTH MAKES NO WARRANTIES, EXPRESS OR IMPLIED, AS TO THE MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF LICENSED PRODUCTS

 ARTICLE VIII. Infringement Matters 

Section 8.01 Infringement by Third Parties. Company shall give Dartmouth prompt notice of any incident of infringement of Joint
Patent Rights coming to its attention. Company agrees to use reasonable efforts to stop any such infringement, but shall not be obliged to commence proceedings against the infringer. If Company decides to commence proceedings however, Company shall
be responsible for any legal costs incurred and will be entitled to retain any damages recovered other than payments otherwise due to Dartmouth hereunder. Financial recoveries from any such litigation will first be applied to reimburse Company for
its litigation expenditures and to reimburse any litigation fees or pay other recoveries due to sublicensees (if applicable) from the settlement, with additional recoveries being paid to Company, subject to payments due Dartmouth per
Section 5.01 (c). Should Company or applicable sublicensee decide not to commence proceedings, Dartmouth shall be entitled to do so in its own name against the infringer, in which event Dartmouth shall be responsible for all legal costs
incurred, without recourse to Company. Financial recoveries from any such Dartmouth-initiated litigation (i.e., from Dartmouth acting subsequent to Company declining to act) will be retained fully by Dartmouth, once litigation expenses actually
incurred by Reata or any Reata sublicense are paid. In any action to enforce Joint Patent Rights, either party, at the request and expense of the other party shall cooperate to the fullest extent reasonably possible, including by agreeing to
participate in such action as a named party, if necessary to maintain the action. Company may not settle any infringement action in any way detrimental to Dartmouth Patent Rights without the expressed written consent of Dartmouth. 

  
 pg. 7 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 ARTICLE IX. Duration and Termination 

Section 9.01 Term. This Agreement shall become effective upon the date first written above, and unless sooner terminated in
accordance with any of the provisions herein, shall remain in full force during the life of the last to expire patents under Dartmouth Patent Rights contemplated by this agreement in the last to expire territory. If mutually desired, the parties may
negotiate for an extension of this License. Upon the termination of the Agreement Company shall have the right to sell the remainder of the Licensed Product on hand, provided the sales will be subject to the royalty payments of this Agreement. 

Section 9.02 Termination - Breach. In the event that either party defaults or breaches any of the provisions of this
Agreement, the other party shall have the right to terminate this Agreement by giving written notice to the defaulting party, provided, however, that if the said defaulting party cures said default within thirty (30) days after said notice
shall have been given, this Agreement shall continue in full force and effect. The failure on the part of either of the parties hereto to exercise or enforce any right conferred upon it hereunder shall not be deemed to be a waiver of any such right
nor operate to bar the exercise or enforcement thereof at any time or times thereafter. 
 Section 9.03 Termination at Will.
Company shall have the right to terminate this Agreement by giving three (3) months advance written notice to Dartmouth to that effect and paying a termination fee of $[***]. Upon termination, a final report shall be submitted and royalty and
other payments due under Article V, as well as unreimbursed patent expenses due Dartmouth become immediately payable. Upon receipt of the termination notice, Dartmouth should be free to start negotiations with a third party for the rights granted
herein. 
 Section 9.04 Insolvency. In the event that Company shall become insolvent, shall make an assignment for the benefit
of creditors, or shall have a petition in bankruptcy filed for or against it, the Agreement shall terminate. 
 Section 9.05 Prior
Obligations and Survivability. Termination of this Agreement for any reason shall not release either party from any obligation theretofore accrued. Sections 3.02, 5.01- 5.03, 7.01- 7.03, 9.03, 10.01 - 10.09 shall survive the termination
of this Agreement. 
 ARTICLE X. Miscellaneous 

Section 10.01 Governing Law. This Agreement shall be construed, governed, interpreted and enforced according to the laws of the
State of Delaware. 
 Section 10.02 Notices. Any notice or communication required or permitted to be given by either party
hereunder, shall be deemed sufficiently given, if mailed by certified mail, return receipt requested, and addressed to the party to whom notice is given as follows: 

If to Company, to: 
 J. Warren Huff 

CEO 
 Reata Pharmaceuticals, Inc.

 2801 Gateway Drive 
 Irving,
TX 75063-2648 

  
 pg. 8 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 If to Dartmouth, to: 

Alla Kan 
 Director 

Technology Transfer Office 

Dartmouth College 
 11 Rope Ferry
Road 
 Hanover, NH 03755 

Section 10.03. Assignment. Except in connection with the sale of substantially all of Company’s assets to a third party, or
in the case of a merger, consolidation or a similar transaction, which will require written notice to Dartmouth and not Dartmouth’s consent, neither party shall assign or transfer this Agreement without the express prior written consent of the
other, such consent not to be unreasonably withheld,. For purposes of this Agreement, an assignment or transfer of this Agreement by COMPANY shall be deemed to occur in connection with (a) an express assignment or transfer, (b) a general
assignment for the benefit of creditors or in connection with any bankruptcy or other debtor relief law, (c) any merger or consolidation to which COMPANY is a party, regardless of whether COMPANY is the surviving corporation, or (d) any
other transaction pursuant to which a change would occur in the “ultimate parent entity” of COMPANY, applying the rules in effect from time to time under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. 

Section 10.04 Entire Agreement. This Agreement represents the entire Agreement between the parties as of the effective date
hereof, and may only be subsequently altered or modified by an instrument in writing. This agreement cancels and supersedes any and all prior oral or written agreements between the parties which relate to the subject matter of this Agreement. 

Section 10.05 Mediation and Arbitration. Both parties agree that they shall attempt to resolve any dispute arising from this
Agreement through mediation. Both parties agree that at least one employee, capable of negotiating an agreement on behalf of his employer, shall, within three weeks of receipt of written notification of a dispute, meet with at least one employee of
the other party who is also capable of negotiating an agreement on behalf of his employer. If no agreement can be reached, both parties agree to meet again within a four week period after the initial meeting; with a neutral third party acceptable to
both Dartmouth and Company present to facilitate such second meeting, to negotiate in good faith to resolve the dispute. If no agreement can be reached after this second meeting, both parties agree to submit the dispute to binding arbitration under
the Rules of the American Arbitration Association before a three member arbitration panel comprised of one member chosen by each party, who shall then jointly appoint the third member of the arbitration panel. 

Section 10.06 Waiver. A failure by one of the parties to this Agreement to assert its rights for or upon any breach or default of this
Agreement shall not be deemed a waiver of such rights nor shall any such waiver be implied from acceptance of any payment. No such failure or waiver in writing by any one of the parties hereto with respect to any rights, shall extend to or affect
any subsequent breach or impair any right consequent thereon. 
 Section 10.07 Severability. The parties agree that it is the
intention of neither party to violate any public policy, statutory or common laws, and govern- mental or supranational regulations; that if any 

  
 pg. 9 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 
sentence, paragraph, clause or combination of the same is in violation of any applicable law or regulation, or is unenforceable or void for any reason whatsoever, such sentence, paragraph, clause
or combinations of the same shall be inoperative and the remainder of the Agreement shall remain binding upon the parties. 

Section 10.08 Marking. Company agrees to mark the Licensed Products with all applicable trademarks, and patent numbers. 

Section 10.09 Headings. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not
constitute a part hereof. 

  
 pg. 10 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement, in duplicate originals, by their respective
officers hereunto duly authorized, the day and year herein written. 
  

			
	THE TRUSTEES OF DARTMOUTH COLLEGE
		
	By	 	 /s/ Alla Kan

		
	Date	 	December 16, 2009
		
	Name	 	Alla Kan
	Title	 	Director, Technology Transfer Office
	
	REATA PHARMACEUTICALS, INC.
		
	By	 	 /s/ Warren Huff

		
	Date	 	12/16/2009
		
	Name	 	Warren Huff
	Title	 	CEO

  
 pg. 11 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN
REQUESTED. THESE REDACTED TERMS HAVE BEEN MARKED IN THIS EXHIBIT WITH THREE ASTERISKS [***]. AN UNREDACTED VERSION OF THIS EXHIBIT HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

Execution Copy 

AMENDMENT NO. 1 TO 2009 LICENSE AGREEMENT 

Amendment No. 1, dated as of July 9, 2012 (the “Amendment”), to the Reata Pharmaceuticals Inc. - Dartmouth Exclusive
License Agreement, effective December 16, 2009 (the “Agreement”), by and between TRUSTEES OF DARTMOUTH COLLEGE (collectively “Dartmouth”), said college being a non-profit educational and research institution existing under
the laws of the State of New Hampshire, Hanover, New Hampshire 03755, and REATA PHARMACEUTICALS, INC. (“Reata”), a Delaware corporation having a principal place of business located at 2801 Gateway Drive, Suite 150, Irving, Texas 75063.

 WHEREAS, [***] 
 WHEREAS,
[***]. 
 NOW, THEREFORE, in consideration of the recitals above and the mutual promises contained herein and for other good and valuable
consideration, including the consideration stated in the [***], the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, do hereby agree as follows: 

1. Section 1.03 of the Agreement is hereby amended to read in its entirety as follows: 

“Licensed Products. “Licensed Products” shall mean any product (i) (A) covered by, (B) made, in whole or in part
by the use of, or (C) sold for a use claimed in, the Dartmouth Patent Rights or (ii) which utilizes the Dartmouth Know-How.” 

2. Section 2.03 (Patents) of the Agreement is hereby amended to read in its entirety as follows: 

“Company shall control all aspects of preparation, filing, prosecution, maintenance, and enforcement of Dartmouth Patent Rights, and shall
be responsible for all costs thereof except as otherwise provided herein. Dartmouth shall have the right to review and provide comments to Company on amendments, responses to office actions, and other submissions to patent authorities. The costs of
such consultations shall be reimbursed to Dartmouth by Company. All such amendments, responses and other submissions shall be submitted to Dartmouth for its consideration at least fourteen days in advance of actual filing and no amendment of any
claim of a pending application or issued patent that diminishes the scope of that claim may be made without Dartmouth’s written consent. Company will reasonably consider comments and suggestions provided by Dartmouth regarding amendments that
do not diminish the scope of any such claim, responses and other submissions, but shall have no obligation to act upon such comments 

 
and suggestions. Company and Dartmouth shall continue using the firm of Fulbright & Jaworski L.L.P., or a successor firm chosen by Company and reasonably acceptable to Dartmouth, for the
preparation, filing, prosecution and maintenance of Dartmouth Patent Rights. If Company chooses to discontinue prosecution or maintenance of any United States Patent or Patent Application, which is a subject of Dartmouth Patent Rights, it will so
inform Dartmouth at least thirty days before implementation of such decision. Dartmouth then shall have the right to prosecute or maintain such Patent or Patent Application on its own and at its own expense, in which case the license to Company
under such Patent or Patent Application will terminate. Company shall notify Dartmouth by at least three (3) months before a National Phase deadline whether it will support the filing, prosecution, or maintenance of patent applications in
particular foreign territories. If Company decides not to support the filing, prosecuting, or maintaining of foreign applications, Dartmouth reserves the right to file, prosecute, or maintain such applications on its own, in which case the license
to Company in the particular territory will terminate. The decision by Company to abandon any particular Patent, Patent Application and/or foreign application will relieve Company from any further diligence or commercialization obligations of
Company in the applicable territory.” 
 3. Section 5.01 of the Agreement is hereby amended to add the following
Section 5.01(h) to Section 5.01: 
 “(h) a sublicense fee of $[***] within 30 days [***]: 

4. Section 5.03 of the Agreement is hereby amended to add the following sentence as the last sentence of Section 5.03: 

“The second and third sentences of this Section 5.03 shall not apply to amounts payable under Section 5.01(f) and 5.01(g) of
this Agreement.” 
 5. Section 9.02 of the Agreement is hereby amended to add the following at the beginning of the first sentence
of Section 9.02: 
 “Subject to the provisions of Article Xl,” 

6. Section 10.03 of the Agreement is hereby amended to read in its entirety as follows: 

“Company may not assign this Agreement without the prior written consent of Dartmouth, which consent will not be unreasonably withheld. A
sale of substantially all of Company’s assets to a third party, a merger, consolidation or similar transaction involving Company or an issuance of its capital stock by, or sale of capital stock of, Company shall not constitute an assignment of
this Agreement. Promptly after the consummation of a sale of substantially all of 

  
 2 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 
Company’s assets to a third party, a merger, consolidation or similar transaction involving Company or an issuance of its capital stock by, or sale of capital stock of, Company (if in each
case such issuance or sale represents a majority of the outstanding shares of capital stock of Company), Company shall give written notice thereof to Dartmouth.” 

7. Section 10.05 of the Agreement is hereby amended by adding the following sentence as the last sentence of Section 10.05: 

“The provisions of this Section 10.05 will not apply to any dispute or controversy to which the provisions of Article XI are
applicable.” 
 8. The following new Article XI is hereby added to the Agreement: 

“ARTICLE XI. ROYALTY DISPUTE RESOLUTION 

Notwithstanding the provisions of Section 10.05 of this Agreement to the contrary, the provisions of this Article XI shall control the
resolution of any dispute arising between the parties under Sections 5.01(f) or 5.01(g) of this Agreement (individually a “Royalty Provision”). There shall be a mandatory audit of payments due to Dartmouth every two years beginning on the
date which is the second anniversary of the first payment due from Company under Section 5.01(f) or Section 5.0l(g), as applicable. The auditor shall be a firm selected by Dartmouth and shall act solely as the agent of Dartmouth. The cost
of the audit, including the fees and expenses of the auditor, shall be paid by Company. Company shall make available to the auditor at the offices of Company, for inspection and copying, all books and records that are reasonably requested by the
auditor and that relate to Net Sales for which a royalty is payable during the applicable audit period; provided, however, that Company may redact any commercial or proprietary information that does not diminish or limit the auditor’s ability
to calculate Net Sales; and provided further that prior to making such books and records available, the auditor and Dartmouth shall first execute a confidentiality agreement that is reasonably acceptable to Company and to which Company is a party
pursuant to which the auditor and Dartmouth (including its attorneys) have agreed to keep confidential and not disclose to third parties or use any non-public information of Company, other than (i) disclosure to the Accounting Arbitrator
(hereafter defined) pursuant to any accounting arbitration proceeding or (ii) use in connection with the inspections and accounting arbitration proceedings provided by this Article XI. The auditor may provide to Dartmouth (including its
attorneys) documents and information that the auditor has reviewed or obtained in the course of the auditor’s investigation, and shall not be required to disclose to Company any advice provided by the auditor to Dartmouth. If Dartmouth (an
“Objecting Party””) objects to Company’s calculation of any payment due under a Royalty Provision, then the Objecting Party shall provide notice in writing to Company of its objection within thirty (30) days after the
completion of the audit as determined 

  
 3 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 
by the auditor, and shall set forth, in writing and in reasonable detail, the basis of such objection. If an Objecting Party fails to deliver such notice of objection within the foregoing time
period, then Company’s calculation of such payment shall be deemed accepted by Dartmouth, and shall become final and binding on the parties to this Agreement. If an Objecting Party gives a written objection notice complying with the foregoing
requirements within the applicable time period, then Company and 
 the Objecting Party shall attempt in good faith, for a period of thirty
(30) days following receipt by Company of such notice, to resolve any dispute concerning the item(s) subject to such notice. If Company and the Objecting Party are unable to resolve the dispute during such 30-day period, then, at the request of
either such party, Company and the Objecting Party shall refer the matter to the Accounting Arbitrator within fourteen (14) days following the expiration of such 30-day period to resolve the matters in dispute, and the determination of the
Accounting Arbitrator in respect of each matter remaining in dispute shall be conclusive and binding on Company and the Objecting Party. If any disputed matters are submitted to the Accounting Arbitrator, Company and the Objecting Party shall each
enter into a reasonable customary engagement letter with the Accounting Arbitrator at the time such matters are submitted to the Accounting Arbitrator, in which each of the Accounting Arbitrator and Dartmouth (including its attorneys) agree to keep
confidential and not to use or disclose any non-public information of Company to any third party other than use in connection with such accounting arbitration proceeding. Subject to the execution of such engagement agreement, Company shall provide
to the Accounting Arbitrator copies of any or all of the books and records of Company that were provided to the auditor by Company that are requested in writing to be provided by Dartmouth to the Accounting Arbitrator. Each of Company and the
Objecting Party may present a supporting brief and provide any supplemental materials to the Accounting Arbitrator (and provide a copy thereof to the other party) within thirty (30) days after the appointment of the Accounting Arbitrator.
Within fourteen (14) days after receipt of a supporting brief and any supplemental materials, the receiving party may present a responsive brief and supplemental materials to the Accounting Arbitrator (and provide a copy thereof to the other
party). If either the Objecting Party or Company wishes to make an oral presentation to the Accounting Arbitrator, a hearing shall be held by the Accounting Arbitrator within thirty (30) days after the submission of such responsive brief and
materials, which shall be attended by all parties to the dispute. The Accounting Arbitrator shall deliver to Company and the Objecting Party as promptly as practicable a written report setting forth the resolution of any such disputed matters. The
Accounting Arbitrator shall elect the position of either Company or the Objecting Party on an item-by-item basis as the resolution for each disputed matter based upon which position is more nearly correct and shall not impose an alternative
resolution with respect to any item of disagreement. The Accounting Arbitrator shall make its determination based solely on the briefs, presentations and supporting material provided by the parties and not pursuant to any independent review. The
determination of the Accounting Arbitrator shall be final and binding on Company and the 

  
 4 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Objecting Party and shall constitute an arbitral award that is final, binding and unappealable
and upon which a judgment may be entered by a court having jurisdiction thereof. Notwithstanding any other provision of this Agreement to the contrary, (i) in the event the aggregate underpayment by Company is equal to or less than [***]
Dollars ($[***]), then such underpayment amount shall bear interest at the rate of [***] percent ([***]%) above the prime rate, or successive prime rates, in effect at The JP Morgan Chase Bank from the date when such payment was due or if such
underpayment is composed of amounts due on more than one date, interest on each constituent amount shall be calculated from the applicable due date of such constituent amount or (ii) in the event that the aggregate underpayment by Company is
greater than [***] Dollars ($[***]), then all such underpayments shall bear interest at the rate of [***] percent ([***]%) from the date when such payment was due (i.e., if the underpayment is composed of amounts due on more than one date, interest
on each constituent amount shall be calculated from the applicable due date of such constituent amount). LICENSEE may reduce, without interest, a future royalty amount owed to LICENSORS in an amount equal to any overpayment of royalty payment made
by LICENSEE to LICENSORS. Each party shall bear its own expenses of the accounting arbitration. However, the fees and expenses of the Accounting Arbitrator shall be allocated between Company and the Objecting Party so that the Objecting Party’s
share of such fees and expenses shall be equal to the product of (i) the aggregate amount of such fees and expenses, multiplied by (ii) a fraction, the numerator of which is the amount in dispute that is ultimately unsuccessfully disputed
by the Objecting Party (as determined by the Accounting Arbitrator), and the denominator of which is the total amount in dispute, and Company’s share of such fees and expenses shall be equal to the aggregate amount of all fees and expenses of
the Accounting Arbitrator minus the Objecting Party’s share of such fees and expenses. Prior to the determination of the final allocation of the fees and expenses of the Accounting Arbitrator, such fees and expenses (if due) shall be paid 50%
by Company and 50% by the Objecting Party, with appropriate reimbursement being made after the final allocation of such fees and expenses. For purposes of this Article XI, the term “Accounting Arbitrator” shall mean any of the independent
accounting firms of Deloitte, Ernst & Young, PricewaterhouseCoopers, KPMG, McGladrey & Pullen, LLP, Grant Thornton, LLP, BKD - Baird, Kurtz & Dobson, Clifton Gunderson and Mayer Hoffman McCann, so long as the performance
by the applicable accounting firm under this Article XI would not cause such accounting firm to lose its status as an “independent accountant” within the meaning Rule 20l(b) of Regulation S-X of the Securities and Exchange Commission to
either Company or the Objecting Party. The Objecting Party shall select the Accounting Arbitrator for the applicable dispute under this Article XI; provided, however, that if a particular accounting firm has served as the Accounting Arbitrator for
an immediately preceding dispute under this Article XI, then the Objecting Party shall select a different accounting firm from 

  
 5 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 
the one of the firms named above to serve as the Accounting Arbitrator for the then current dispute under this Article XI. If none of the listed accounting firms is qualified, available or
willing to serve as the Accounting Arbitrator, the Objecting Party will select another firm subject to the reasonable approval of Company. Notwithstanding any provision of Section 9.02 of this Agreement to the contrary, Dartmouth shall not have
the right to declare or give notice of a default or breach of this Agreement or terminate this Agreement as to any dispute or controversy covered by the provisions of this Article XI; provided, however, that any breach by Company of its obligations
under this Article XI, other than any failure to pay any amount determined by the Accounting Arbitrator to be owed to Dartmouth pursuant to the provisions of this Article Xl, that is not cured within thirty (30) days after the receipt of
written notice by the Objecting Party, and any failure to pay any amount determined by the Accounting Arbitrator to be owed to Dartmouth pursuant to the provisions of this Article XI, including any interest payable with respect to any such amount,
within ten (10) days after any such determination shall entitle the Objecting Party to terminate this Agreement without further notice to Company and without affording Company a further opportunity to cure such breach or default 

9. Except as amended by this Amendment, the Agreement shall remain in full force and effect pursuant to its terms. 

10. Terms not otherwise defined in this Amendment shall have the meaning set forth in the Agreement. 

11. This Amendment may be executed in one or more counterparts all of which together shall constitute one and the same agreement. The delivery
by any party of an executed counterpart hereof by facsimile transmission or email of .pdf copies shall be effective as an original executed counterpart of this Amendment by such party and shall constitute an original enforceable document. 

[signatures set forth on the following page] 

  
 6 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 IN WITNESS WHEREOF, the parties have duly executed this Amendment as of the date first written
above. 
  

			
	REATA PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Warren Huff

	Name:	 	Warren Huff
	Title:	 	Chief Executive Officer
	
	TRUSTEES OF DARTMOUTH COLLEGE
		
	By:	 	 /s/ Martin N. Wybourne

	Name:	 	Martin N. Wybourne
	Title:	 	Interim Provost and Vice Provost for Research

  
 7 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission.EX-10.9

 Exhibit 10.9 
  

					
	KUCTC-Reata	 	Confidential	  	[***]

 SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THESE REDACTED TERMS HAVE BEEN MARKED IN THIS EXHIBIT WITH THREE ASTERISKS [***]. AN UNREDACTED VERSION OF THIS EXHIBIT HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

EXCLUSIVE LICENSE AGREEMENT 

between 
 Reata
Pharmaceuticals, Inc. 
 and 

KU Center for Technology Commercialization, Inc. 

Exclusive License Agreement 

  
 Page i of
34 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 TABLE OF CONTENTS 

 

					
	 ARTICLE l. DEFINITIONS
	  	 	3	  
	 ARTICLE 2. LICENSE GRANT
	  	 	6	  
	 ARTICLE 3. TERM OF AGREEMENT
	  	 	7	  
	 ARTICLE 4. FEES & ROYALTIES
	  	 	7	  
	 ARTICLE 5. COMMERCIAL DILIGENCE & MILESTONES
	  	 	10	  
	 ARTICLE 6. EQUITY OWNERSHIP
	  	 	12	  
	 ARTICLE 7. CONFIDENTIALITY
	  	 	12	  
	 ARTICLE 8. QUARTERLY & ANNUAL REPORTS
	  	 	13	  
	 ARTICLE 9. PAYMENTS, RECORDS and AUDITS
	  	 	14	  
	 ARTICLE 10. PATENT MARKING
	  	 	15	  
	 ARTICLE 11. PATENT PROSECUTION AND MAINTENANCE
	  	 	15	  
	 ARTICLE 12. TERMINATION BY LICENSOR
	  	 	16	  
	 ARTICLE 13. TERMINATION BY LICENSEE
	  	 	16	  
	 ARTICLE 14. DISPOSITION OF LICENSED PRODUCTS ON HAND
	  	 	16	  
	 ARTICLE 15. WARRANTY BY LICENSOR
	  	 	17	  
	 ARTICLE 16. INFRINGEMENT
	  	 	17	  
	 ARTICLE 17. INSURANCE
	  	 	18	  
	 ARTICLE 18. WAIVER
	  	 	18	  
	 ARTICLE 19. ASSIGNABILITY
	  	 	18	  
	 ARTICLE 20. INDEMNIFICATION BY LICENSEE
	  	 	19	  
	 ARTICLE 21. NOTICES
	  	 	19	  
	 ARTICLE 22. REGULATORY COMPLIANCE
	  	 	19	  
	 ARTICLE 23. GOVERNING LAW
	  	 	20	  
	 ARTICLE 24. RELATIONSHIP OF PARTIES
	  	 	20	  
	 ARTICLE 25. USE OF NAMES
	  	 	20	  
	 ARTICLE 26. DISPUTE RESOLUTION
	  	 	20	  
	 ARTICLE 27. GENERAL PROVISIONS
	  	 	21	  
	 EXHIBIT “A”
	  	 	23	  
	 PATENT RIGHTS
	  	 	23	  
	 EXHIBIT “B”
	  	 	25	  
	 LICENSE TO THE UNITED STATES GOVERNMENT
	  	 	25	  
	 EXHIBIT “C”
	  	 	26	  
	 XXXX ROYALTY REPORT
	  	 	26	  
	 EXHIBIT “D”
	  	 	28	  
	 ANNUAL DEVELOPMENT and COMMERCIALIZATION REPORT
	  	 	28	  
	 EXHIBIT “E”
	  	 	30	  
	 CURRENT DEVELOPMENT PLAN
	  	 	30	  
	 EXHIBIT “F”
	  	 	31	  
	 MATERIAL TRANSFER AGREEMENT TEMPLATE
	  	 	31	  

 LICENSE AGREEMENT 

THIS LICENSE Agreement (“Agreement”) is entered into this 26th day of September, 2014 by and between the KU CENTER FOR TECHNOLOGY
COMMERCIALIZATION, INC, a Kansas non-profit § 501(c)(3) corporation, having its principal place of business at 3901 Rainbow Boulevard, Kansas City, Kansas 66160, hereinafter referred to as “KUCTC” or “Licensor,” and
“REATA PHARMACEUTICALS, INC.” having its principal place of business at 2801 Gateway Drive, Suite 150, Irving, Texas 75063, hereinafter referred to as “Licensee.” 

  
 Page 2 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 WITNESSETH 

WHEREAS, certain inventions, generally characterized as small molecule modulators of heat shock proteins and assigned KUCTC Technology ID
numbers [***], and [***], hereinafter collectively referred to as “the Invention”, have been made in the course of research at the University of Kansas conducted by Dr. Brian Blagg, et al., and are Covered By Patent Rights (as defined
below); 
 WHEREAS, the University of Kansas and the University of Kansas Medical Center (hereinafter collectively referred to as
“KU”) and KUCTC have an agreement wherein KUCTC is the manager of intellectual property owned by KU; 
 WHEREAS, the Inventions
have been and/or will be developed by employees, students, or postdoctoral fellows of KU; and 
 WHEREAS, KU and KUCTC together own all
right, title and interest in the Inventions and the Patent Rights; and 
 WHEREAS, Licensor desires that the Patent Rights be developed and
utilized to the fullest extent so that their benefits can be enjoyed by the general public; 
 WHEREAS, Licensee wishes to obtain from
Licensor a license under certain patent rights for the commercial development, production, manufacture, use and sale of Licensed Products and Licensor is willing to grant such a license upon the terms and conditions hereinafter set forth; 

WHEREAS, the Patent Rights were developed in the course of research sponsored in part by the U.S. Government, and as a consequence are subject
to overriding obligations of Licensor to the U.S. Government; 
 NOW THEREFORE, for and in consideration of the covenants, conditions and
undertakings hereinafter set forth, the parties hereby agree as follows: 
 ARTICLE l. DEFINITIONS 

 

	1.1	“Affiliate” means any company or other business entity that, directly or indirectly, controls, or is controlled by, or is under common control by Licensee. Solely for purposes of this definition, the
term “control” means the possession of the power to direct or cause the direction of the management and policies of the entity, whether through ownership of voting securities or by contract. Control will be presumed if an entity owns,
either of record or beneficially, at least fifty percent (50%) of the voting stock of the other entity. An entity will be deemed an Affiliate only while such ownership or control relationship continues. 

 

	1.2	“Clinical Candidate” means a compound which, following Lead Optimization, has been designated by Licensee for entry into GLP Toxicology Studies and other IND-directed research activities.

  

	1.3	“...Covered By...” means a compound, composition, product, process, method or other substance or activity, the use, manufacture, or sale of which would infringe a Valid Claim within any pending or
issued patent included in the Patent Rights claiming all, a portion, or a component or step of a Licensed Product. 

  

	1.4	“Commercially Diligent Efforts” means, with respect to a Licensed Product, the diligent exercise, dedication and expenditure of efforts, money, personnel, and resources as reasonably needed to develop,
manufacture, market and sell the Licensed Product. Such efforts shall be documented and must be consistent with those utilized by companies of similar size and type that have successfully developed products and services similar to the Licensed
Product. In determining Commercially Diligent Efforts with respect to a particular Licensed Product, Licensee may not reduce such efforts due to the competitive, regulatory or other impact of any other product or method that it owns, licenses or is
developing or commercializing. 

  
 Page 3 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	1.5	“Effective Date” means the latest date upon which an authorized representative of Licensee or Licensor signs this Agreement. 

 

	1.6	“Entity” means a corporation, an association, a joint venture, a partnership, a trust, a business, an institution, an individual, a government or political subdivision thereof, including an agency, or
any other organization that can exercise independent legal standing. 

  

	1.7	“Fair Market Value” means the cash consideration which Licensee or its Sublicensee would realize from an unaffiliated, unrelated buyer in an arm’s length sale of an identical item sold in the same
quantity, under the same terms, and at the same time and place. 

  

	1.8	“FDA” means the United States Food and Drug Administration. 

  

	1.9	“Field of Use” means all human and veterinary therapeutic and diagnostic uses. 

  

	1.10	“First Dosing”, with respect to human clinical trials, means the first administration of a Licensed Product to a subject in a specified clinical trial. 

 

	1.11	“GLP Toxicology Studies” means a non-clinical toxicology study conducted according to Good Laboratory Practices guidelines promulgated by the FDA, and intended to support submission of an IND.

  

	1.12	“IND” means an investigational new drug application filed with the FDA for authorization to commence Clinical Studies in the U.S. or an equivalent application filed with the applicable Regulatory
Authority in another country or regulatory jurisdiction. 

  

	1.13	“IND Acceptance” means that either by issuing no comment during the 30-day IND review period or by providing some affirmative communication, the FDA has assented to the performance of the clinical trial
proposed in the IND application. 

  

	1.14	“Initiation” means, with respect to a study in non-human mammals, the first dosing of a live subject in a study. 

  

	1.15	“Insolvent” means being unable to meet one’s debt obligations to another Entity as such debt obligations become due and not being able to provide reasonable financial assurances of becoming able to
meet such obligations. 

  

	1.16	“Lead Compound” means an organic compound identified in screening assays and in vivo studies that shows sufficient activity to be a standard of comparison in medicinal chemistry research programs
intended to identify additional compounds having superior potency, selectivity, in vivo activity, or other superior drug-like qualities. 

  

	1.17	“Lead Optimization” means the program of medicinal chemistry research intended to identify structure-activity relationships and apply the knowledge of those relationships to produce compounds having
superior properties relative to a Lead Compound. 

  

	1.18	“Licensed Product” means any product, process, method of use, apparatus, kit or component part thereof, or any other subject matter, the manufacture, design, creation, use, importation, distribution, or
sale of which is Covered By any Valid Claim. 

  
 Page 4 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	1.19	“NDA” means New Drug Application according to FDA regulations, or the foreign equivalent. 

  

	1.20	“NDA Acceptance” means receipt of a communication from the FDA stating that a filed NDA has been accepted for review. 

 

	1.21	“Net Sales” means the gross amount invoiced by LICENSEE, AFFILIATE and/or any Sublicensee for the SALE of LICENSED PRODUCTS to a third party less: (i) normal and customary trade, cash and other
discounts actually granted; (ii) charge back payments and rebates granted to managed health care organizations or to federal, state and local governments, their agencies and purchasers; (iii) commercially reasonable and customary fees paid
to distributors (other than AFFILIATES) that are included in the gross invoiced amount;(iv) credits or allowances actually granted for rejections or returns of LICENSED PRODUCTS, including recalls (not to exceed the original invoiced amount);
(v) sales or similar taxes, including without limitation, value added taxes or other governmental charges which are included in the invoiced amount; and (vi) freight, postage, shipping, customs duties and insurance charges for packaging
which are included in the invoiced amount, all as recorded by LICENSEE in LICENSEE’s official books and records in accordance with generally accepted accounting practices and consistent with LICENSEE’s published financial statements and/or
regulatory filings with the United States Securities and Exchange Commission, or as reported by any Sublicensee to Licensee in compliance with the terms of the relevant sublicense, as applicable. For the avoidance of doubt, sales and transfers among
Licensee and its Sublicensees (for example, transfer of finished drug product from Licensee to a Sublicensee for commercial distribution) of Licensed Products intended for ultimate sale to third parties shall be disregarded for purposes of computing
Net Sales. 

  

	1.22	“Patent Rights” means and include all of the following Licensor intellectual property: The United States patents and/or patent applications listed in Exhibit “A”; United States patents issued
from the applications listed in Exhibit “A” and from divisionals and continuations (other than continuations-in-part) of these applications and any reissues of such United States patents; claims of continuation-in-part applications and
patents directed to subject matter specifically described in the patent(s) and/or patent application(s) listed in Exhibit “A”; and claims of all foreign applications and patents which are directed to subject matter specifically described
in the United States patents and/or patent applications listed in Exhibit “A”. 

  

	1.23	“Phase 1 Clinical Trials” means a human clinical trial of a Licensed Product, the principal purpose of which is a preliminary determination of safety in healthy individuals or patients or similar
clinical study prescribed by the FDA or a comparable foreign regulatory authority, including the trials referred to in 21 C.F.R. §312.21(a), as amended. 

  

	1.24	“Phase 2 Clinical Trials” means a human clinical trial of a Product or a New Collaboration Compound, the principal purpose of which is a determination of safety and efficacy in the target patient
population or a similar clinical study prescribed by the Regulatory Authorities, from time to time, pursuant to Applicable Law or otherwise, including the trials referred to in 21 C.F.R. §312.21(b), as amended. 

 

	1.25	“Phase 3 Clinical Trials” means a human clinical trial of a Product or New Collaboration Compound on a sufficient number of subjects that is designed to establish that a pharmaceutical product is safe
and efficacious for its intended use and to determine warnings, precautions, and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed, which trial is intended to support marketing approval of
such Product or New Collaboration Compound, including all tests and studies that are required by the FDA from time to time, pursuant to Applicable Law or otherwise. 

 

	1.26	“Sublicensee” means any party other than an Affiliate which enters into an agreement or arrangement with Licensee or receives a license grant from Licensee under the Patent Rights, to manufacture, have
manufactured, offer for sale, sell, lease, use, practice, and/or import the Licensed Product, subject to the then-current applicable article, item, service, technology, and technical data-specific requirements of the U.S. export laws and
regulations. 

  

  
 Page 5 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	1.27	“Territory” means worldwide. 

  

	1.28	“Valid Claim” means a claim of any issued and unexpired patent or patent application that is part of Patent Rights, whose validity, enforceability, or patentability has not been affected by any of the
following: (i) irretrievable lapse, abandonment, revocation, dedication to the public, or disclaimer, or (ii) a holding, finding, or decision of invalidity, unenforceability, or non-patentability by a court, governmental agency, national
or regional patent office, or other appropriate body that has competent jurisdiction, such holding, finding, or decision being final and unappealable or unappealed within the time allowed for appeal. 

ARTICLE 2. LICENSE GRANT 
  

	2.1	Exclusive Grant  

 Subject to the terms and conditions set forth herein, Licensor hereby
grants to Licensee a royalty-bearing exclusive license to make, have made, use and sell any Licensed Product in the Field of Use under Licensor’s Patent Rights throughout the Territory. This grant is subject to the payment by Licensee to
Licensor of all consideration required under this Agreement, and subject to any rights of the Government of the United States as set forth in Section 2.2. This grant is further subject to rights retained by Licensor and KU to: 

 

	 	a.	publish the general scientific findings from research conducted in whole or in part at KU related to the Patent Rights; 

  

	 	b.	manufacture, have manufactured, use, or practice the Patent Rights for research, teaching and other educationally-related purposes; and 

 

	 	c.	to permit other qualified non-profit and/or academic research institutions the limited right to use the Patent Rights, to make, have made, and use any Licensed Product for such organizations’ internal
non-commercial research purposes. Any such grant of limited rights to a third party institution, including the transfer of any Licensed Product to any such third party institution or any other third party, shall be contingent upon the execution of a
Material Transfer Agreement or equivalent agreement, substantially in the form of Exhibit “F”, limiting such third party’s activities to a specified research program for a specified period of time and providing Licensee with a right
of first negotiation for exclusive rights to any resulting inventions. No such grant of limited rights to a third party institution shall include the right to conduct any research whatsoever, without the express written consent of Licensee in each
and every instance, with a compound that has been designated by Licensee as a Clinical Candidate or which is under consideration for designation as a Clinical Candidate. As of the Effective Date, such compounds include [***], and the compounds
covered by U.S. provisional patent application [***]. Any such grant of limited rights to a third party institution shall explicitly exclude, at all times, the right to conduct any research whatsoever in humans or administer any Licensed Product to
humans. 

  

	 	d.	Neither KU nor Licensor, nor any Affiliate thereof, shall at any time use any Licensed Product in humans for any purpose whatsoever without the express written consent of Licensee. 

 

	2.2	The license granted in Section 2.1 hereof is expressly made subject to a non-exclusive, irrevocable, royalty-free license heretofore granted to the U.S. Government and in the general form as attached hereto as
Exhibit “B” and incorporated herein by reference. 

  
 Page 6 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	2.3	Affiliates 

 Licensee may extend the license granted herein to any Affiliate if the
Affiliate consents in writing to be bound by this Agreement to the same extent as Licensee; provided, however, that any fee or other consideration paid to Licensee in consideration of such extension will be subject to the provisions of
Section 2.4 as if the Affiliate were a Sublicensee. Other agreements or arrangements with Affiliates relating to Patent Rights which result in the sale of Licensed Product(s) will be subject to the royalty payment and other applicable payment
provisions of this Agreement 
  

	2.4	Sublicensing 

 Licensor hereby grants to Licensee the right to enter into sublicensing
agreements with Sublicensees, provided that Licensee has current exclusive rights thereto in the Territory being sublicensed pursuant to Section 2.1 and subject to the following: 

 

	 	a.	Any sublicense granted by Licensee to a Sublicensee shall incorporate all of the terms and conditions of this Agreement, which shall be binding upon each Sublicensee as if such Sublicensee were a party to this
Agreement. Licensee shall collect and guarantee all payments due Licensor from Sublicensee(s). 

  

	 	b.	If Licensee becomes Insolvent, Licensor’s proportionate share of all payments then or thereafter due and owing to Licensee from its Sublicensees for the sublicense of the Patent Rights will, upon notice from
Licensor to any such Sublicensee, become payable directly to Licensor by Sublicensee for the account of Licensee. 

  

	 	c.	Licensee shall within thirty (30) days of: (a) execution, provide Licensor with a copy of each sublicense granted by Licensee hereunder, and any amendments thereto or terminations thereof; and
(b) receipt, summarize and deliver copies of all reports due to Licensee from Sublicensee(s). 

  

	 	d.	If this Agreement is terminated for any reason, any existing Sublicensee(s) will have the right to assume Licensee’s rights and obligations hereunder in the territory covered by the Sublicense. If any of the United
States, Mexico, or Canada are not covered by any Sublicense, then the Sublicensee having rights in the countries of the European Union shall have the right to assume Licensee’s rights and obligations in any such non-sublicensed country.
Following the termination of this Agreement, the Sublicensee shall execute a license agreement with Licensor. 

 ARTICLE
3. TERM OF AGREEMENT 
 Unless otherwise terminated by operation of law or by acts of the parties pursuant to the terms of this
Agreement, this Agreement shall be in full force and effect from the Effective Date until the later of (a) the end of the term of the last-to-expire of Licensor’s Patent Rights licensed under this Agreement in each country, (b) ten
(10) years from the date of the First Commercial Sale in each country, or (c) the expiration of regulatory exclusivity in each country that effectively bars the commercial sale of a generic version of a Licensed Product by a third party.

 ARTICLE 4. FEES & ROYALTIES 
  

	4.1	License Issue Fee 

 Licensee shall pay to Licensor a non-refundable License Issue Fee of
[***] US Dollars ($[***]) upon execution of this Agreement. Such License Issue Fee shall be deemed earned and immediately payable upon execution of this Agreement; failure to deliver said fee to Licensor on or before ten (10) business days
following execution of this Agreement by both parties shall terminate this Agreement. 

  
 Page 7 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	4.2	License Maintenance Fee 

 Licensee will pay an annual license maintenance fee in the
amount of [***] US Dollars ($[***]), due and payable on each anniversary of the Effective Date beginning on September 26, 2015. 
  

	4.3	Running Royalty 

 As consideration for the license under this Agreement, if a Licensed
Product contains [***] or another compound that is specifically disclosed in one or more of the patents or patent applications listed in Exhibit A, Licensee shall pay to Licensor an earned royalty of [***] percent ([***]%) of Net Sales, whether Net
Sales are achieved by Licensee or by a Sublicensee. For example, if Net Sales by Licensee in a territory are [***] dollars ($[***]), a royalty of [***] dollars ($[***]) will be due to Licensor. If Net Sales by any Sublicensee in a territory are
[***] dollars, a royalty of [***] dollars will be due to Licensor, payable by Licensee. If a Licensed Product contains as its active principle a compound that is not specifically disclosed in one or more of the patents or patent applications listed
in Exhibit A, Licensee shall pay to Licensor an earned royalty of [***] percent ([***]%) of Net Sales, whether Net Sales are achieved by Licensee or by a Sublicensee. Earned royalties shall accrue in each country, the period of time commencing on
the date of the First Commercial Sale in that country and continuing until the later of (a) the expiration of the last to expire Valid Claim in that country covering the manufacture, use or sale of such Licensed Product in such country,
(b) ten (10) years from the date of the First Commercial Sale in that country, or (c) the expiration in that country of regulatory exclusivity that effectively bars the commercial sale of a generic version of a Licensed Product by a
third party. Upon the occurrence in any given country of the later of events (a) through (c) in the preceding sentence, no further royalty shall accrue to Licensor for Net Sales in that country regardless of the amount of sales achieved in
that country by Licensee or any Sublicensee. 
  

	4.4	Minimum Royalty 

 Commencing with the first calendar quarter to occur following the date
of first occurrence of Net Sales, Licensee shall pay to Licensor within forty-five (45) days of the end of said quarter a minimum annual royalty as provided below: 

YEAR 1         [***] US Dollars ($[***]) 

YEAR 2         [***] US Dollars ($[***]) 

YEAR 3         [***] US Dollars ($[***]) 

YEAR 4         [***] US Dollars ($[***]) 

YEAR 5         [***] US Dollars ($[***])         (and Beyond)

 Licensee shall continue to pay such minimum annual royalty until the end of the term of the last to expire of Licensor’s Patent
Rights. Licensor shall fully credit each payment of minimum annual royalties against any earned royalties payable by Licensee with respect to the year in which the minimum annual royalty is made. 

 

	4.5	Sublicense Fees and Royalties 

 Licensee shall pay to Licensor the percentage specified
below of any lump sum fee that is not an earned royalty, any fixed fee, license fee, milestone payment, unearned portion of any minimum royalty payment, joint marketing fee, intellectual property cross license, and any other property,
consideration or thing of value given or exchanged as compensation for a sublicense (collectively, “Sublicense Income”). All such consideration received by Licensee shall be fully auditable by

  
 Page 8 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 
Licensor. If a Sublicensee purchases equity in Licensee in connection with the grant of a sublicense, Licensee and Licensor shall discuss in good faith to determine whether such equity investment
was or was not purchased as compensation for the sublicense grant. Licensee shall not receive from Sublicensee(s) anything of value in lieu of cash payments in consideration for any sublicense under this Agreement without the express prior written
permission of Licensor. Any non-cash consideration, including, without limitation, equity in other companies or equity investments in Licensee, received by the Licensee from any Sublicensee(s) will be valued at its Fair Market Value as of the
date of receipt by Licensee. 
 If additional technologies owned or licensed by Licensee are included in a sublicense agreement that grants
rights under this Agreement, the parties hereto will reasonably allocate value among the Patent Rights and the other technologies included in the sublicense and the Sublicense Income percentages set forth below shall be adjusted accordingly,
resulting in the Sublicense Income percentages below being applied only to the portion of the total license value that is allocated to the Patent Rights, provided that in no event shall the value allocated to the Patent Rights be less than % of the
total value of the Patent Rights and such other technologies. Additional technologies owned or licensed by Licensee are deemed to contribute no value if (1) they are a product, process or usage that falls within the scope of any Valid Claim and
(2) the filing date of the Patent Rights predates the filing date of the additional Licensee owned or licensed patent rights included in the sublicense. 
  

			
	 Project Status at Time of Sublicense
	  	 Sublicense Income Percentage

		
	[***]	  	[***]% ([***] percent of Sublicense Income received by Licensee)
		
	[***]	  	[***]% ([***] percent of Sublicense Income received by
		
	[***]	  	Licensee)
		
	[***]	  	
		
	[***]	  	[***]% ([***] percent of Sublicense Income received by
		
	[***]	  	Licensee)
		
	[***]	  	
		
	[***]	  	[***]% ([***] percent of Sublicense Income received
		
	[***]	  	by Licensee)
		
	[***]	  	
		
	[***]	  	[***]% ([***] percent of Sublicense Income received by Licensee)
		
	[***]	  	
		
	[***]	  	
		
	[***]	  	[***]% ([***] percent of Sublicense Income received [***] by Licensee)

  
 Page 9 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	4.6	Past Patent Expenses 

 Licensee shall reimburse past patent expenses incurred by Licensor
in filing and prosecuting patent applications included in the Patents Rights according to the following payment plan. As of September 15, 2014, these expenses are estimated at [***] US Dollars ($[***]) (“Past Patent Expenses”). 

 

	 	(a)	As partial reimbursement of Past Patent Expenses, Licensee shall pay to Licensor [***] US Dollars ($[***]) within Fifteen (15) calendar days following initiation of GLP Toxicology Studies with a Licensed Product by
Licensee. 

  

	 	(b)	As partial reimbursement of Past Patent Expenses, Licensee shall pay to Licensor [***] US Dollars ($[***]) within Fifteen (15) calendar days following completion of 28-day non-rodent GLP Toxicology Studies with a
Licensed Product resulting in an Acceptable Toxicity Profile. 

 The payments in 4.6 (a) and (b) above shall be
payable whether the stipulated event is first achieved with a Licensed Product under this Agreement or a Licensed Product under the terms of the Exclusive License Agreement between KUCTC and Licensee, contract number [***]. Achievement of these
events with a Licensed Product under this Agreement shall also satisfy the requirements for reimbursement of Past Patent Expenses under contract number [***]. 

“Acceptable Toxicity Profile” shall be defined as a body of results that is suitable to support IND filing for the proposed
indication, including but not limited to a defined no-adverse-effect-level (NOAEL) that would provide an appropriate safety margin to support clinical development. 

Licensee shall pay all future patent expenses as set forth in Article 10 hereof. 

ARTICLE 5. COMMERCIAL DILIGENCE & MILESTONES 
  

	5.1	Commercial Diligence 

 Upon execution of this Agreement, Licensee shall diligently
proceed with Commercially Diligent Efforts to develop, manufacture, practice, sell and use the Licensed Products in order to make them readily available to the general public as soon as possible on commercially reasonable terms. Licensee shall
continue active, diligent Commercially Diligent Efforts for one or more Licensed Product(s) throughout the term of this Agreement (“Actively Commercializing”). In addition, Licensee shall perform at least the following obligations as part
of its due diligence activities hereunder: 
  

	 	(a)	Licensee shall [***]. 

  

	 	(b)	Licensee shall [***]. 

  

	 	(c)	Licensee shall [***]. 

  

	 	(d)	Licensee [***]. 

 Meeting each milestone one time will satisfy Commercial Diligence requirements
in Section 5.1, regardless of the number of compounds that are ultimately developed. Achievement of one or more of the above milestones with [***] or another compound that is a Licensed Product under the terms of the Exclusive License Agreement
between KUCTC and Licensee, contract number [***], and payment of the associated fee(s) pursuant to section 5.2 of that Agreement, will satisfy Commercial Diligence requirements hereunder with respect to any such milestone(s) and milestone
payment(s). 

  
 Page 10 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 If, despite using Commercially Diligent Efforts, Licensee is unable to meet any of the
foregoing due diligence milestones, Licensor will grant to Licensee, upon Licensee’s request, [***] extension of time to meet any missed milestone, subject to the following: (i) Licensor would have no obligation to grant Licensee more than
[***] extensions per milestone; (ii) In consideration of each [***] extension that Licensor grants, Licensee would be obligated to pay Licensor an extension fee of [***] Dollars ($[***] USD) for each of the [***] extensions, and (iii) Each
extension granted shall be considered to apply to the specific milestone for which it is granted and to all subsequent milestones, but shall be considered one (1) extension for purposes of clauses (i) and (ii). 

 

	5.2	Milestones and Fees for Development of Licensed Products 

  

	 	a.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon [***]. 

  

	 	b.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon [***]. 

  

	 	c.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon [***]. 

  

	 	d.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon [***]. 

  

	 	e.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon [***]. 

  

	 	f.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon [***]. 

  

	 	g.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon [***]. 

  

	 	h.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon [***]. 

 Each
required payment will be paid to Licensor within thirty (30) days of completion of each milestone listed above. 
 Beginning with IND
acceptance, each milestone may be paid up to [***] times if different compounds are developed in different therapeutic areas, (e.g., [***]). If a back-up or replacement compound is substituted for an initial lead compound in a given indication,
milestones achieved with the back-up or replacement compound will not be payment-bearing until a previously unpaid milestone is reached. For example, if the initially developed compound has entered Phase I and is then replaced, no milestone payments
will be due for the replacement compound until first dosing in a Phase II trial is achieved. These considerations will apply without regard to whether such back-up or replacement compound, or the initial lead compound, is a Licensed Compound under
this Agreement or under the terms of the Exclusive License Agreement between KUCTC and Licensee, contract number [***]. 
  

	5.3	Sales Milestones 

  

	 	a.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon first achievement of worldwide Net Sales of [***] US Dollars ($[***]) for the first Licensed Product. 

 

	 	b.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon first achievement of worldwide Net Sales of [***] US Dollars ($[***]) for the first Licensed Product. 

 

	 	c.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon first achievement of worldwide Net Sales of [***] US Dollars ($[***]) for the first Licensed Product. 

 

	 	d.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon first achievement of worldwide Net Sales of [***] US Dollars ($[***]) for the first Licensed Product. 

  
 Page 11 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	 	e.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon first achievement of worldwide Net Sales of [***] US Dollars ($[***]) for the first Licensed Product. 

Each required payment will be paid to Licensor within thirty (30) days of completion of each milestone listed above. If a product that is
a Licensed Product under the terms of the Exclusive License Agreement between KUCTC and Licensee, contract number [***], achieves Net Sales before any product that is a Licensed Product pursuant to this Agreement has achieved Net Sales, the sales
milestones under this section 5.3 shall no longer be applicable to any Licensed Product hereunder. 
  

	5.4	Sponsored Research 

 Licensee shall spend at least [***] US dollars ($[***]) at KU within
one (1) year of the Effective Date for the development of Licensed Products (“Sponsored Research”). This sponsored research agreement will be renewable annually upon mutual agreement. The Parties agree to negotiate the terms of such
Sponsored Research Agreements in good faith. Support provided pursuant to Licensee’s obligations under Section 5.4 of the Exclusive License Agreement between KUCTC and Licensee, contract number [***], shall be fully applicable to
Licensee’s obligations under this Section 5.4, such that the aggregate amount of support required under both Agreements shall not exceed $[***]. 

ARTICLE 6. EQUITY OWNERSHIP 
 The
parties agree that no equity interest in Licensee will be granted to Licensor or KU in relation to this Agreement. 
 ARTICLE 7.
CONFIDENTIALITY 
  

	7.1	Licensee and Licensor acknowledge that either party may provide certain information to the other with regard to the Inventions that is considered to be confidential. It is therefore agreed that any information received
by one party from the other, and clearly designated at the time of disclosure or promptly thereafter as “CONFIDENTIAL” (“Confidential Information”), shall not be disclosed by either party to any third party other than its outside
legal, accounting, tax and financial advisors, bona fide potential acquirors and potential investors, and potential and existing lenders, financing sources, Sublicensees, consultants, and contractors, provided that they have been informed of the
confidential nature of such information and are bound by confidentiality obligations no less stringent than the obligations contained herein. It is acknowledged and agreed that the financial information contained in this Agreement is Confidential
Information. Confidential Information shall not be used by either party hereto or the third parties enumerated above for purposes other than those contemplated by this Agreement for a period of five (5) years from the termination of this
Agreement, unless or until – 

  

	 	a.	said information becomes known to third parties not under any obligation of confidentiality to the disclosing party, or becomes publicly known through no fault of the receiving party; 

 

	 	b.	contemporaneously dated written records demonstrate that said information was already in the receiving party’s possession prior to the disclosure of said information to the receiving party, except in cases when the
information has been covered by a preexisting confidentiality agreement; 

  

	 	c.	said information is subsequently disclosed to the receiving party by a third party not under any obligation of confidentiality to the disclosing party; 

 

	 	d.	said information is approved for disclosure by prior written consent of the disclosing party; 

  
 Page 12 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	 	e.	said information is required to be disclosed by court order or governmental law or regulation, provided that, except with respect to disclosures required by applicable securities laws or regulations, the receiving party
gives the disclosing party prompt notice of any such requirement and cooperates with the disclosing party in attempting to limit such disclosure; or 

  

	 	f.	said information is proven by contemporaneously dated written records to have been independently developed by the receiving party without recourse or access to the information. 

 

	7.2	Each party hereto acknowledges that the obligations undertaken by it pursuant to this Section are unique and that the other party will have no adequate remedy at law if such party shall fail to perform any of its
obligations hereunder, and such party therefor confirms the other party’s right to specific performance of the terms of this Section is essential to protect the rights and interests of the other party. Accordingly, each party agrees that, in
addition to any other remedies that the other party may have at law or in equity, the other party shall have the right to sue in equity to have all obligations of such party pursuant to this Section specifically performed by such party, and the
other party shall have the right to seek preliminary and permanent injunctive relief to secure specific performance and to prevent a breach or contemplated breach of this Section by such party. Each party hereby expressly waives the defense that a
remedy in damages will be adequate for a breach by it under this Section. Each party further agrees that the other party shall not be required to post a bond as a condition to obtaining or exercising such remedies, and such party hereby waives any
such requirement or condition. 

  

	7.3	Licensee acknowledges that Licensor is subject to the Kansas Open Records Act, K.S.A. 45-215 et seq.. Licensor shall keep confidential any information provided to Licensor by Licensee that Licensee considers
confidential, to the extent allowable under the Kansas Open Records Act. 

 ARTICLE 8. QUARTERLY & ANNUAL
REPORTS 
  

	8.1	Annual and Quarterly Royalty Report 

 Within sixty (60) days after the end of the
calendar year in which Net Sales first occur, and within sixty (60) days after the end of each calendar quarter thereafter, Licensee shall provide Licensor with a written report detailing all sales and uses, if any, made of Licensed Products
during the preceding calendar quarter, and detailing the amount of Net Sales made during such quarter and calculating the royalties due to Licensor pursuant to Article 4 hereof. Each report shall include at least the following: 

 

	 	g.	Amount of Net Sales, on a country-by-country basis, of Licensed Products sold by and/or for Licensee, Affiliates and all Sublicensees; 

 

	 	h.	accounting for Net Sales, noting the deductions applicable as provided in Section 1.21; 

  

	 	i.	total royalties due to Licensor; and 

  

	 	j.	names and addresses of all Sublicensees. 

 Each report shall be in substantially similar form as
Exhibit “C” attached hereto. Each such report shall be signed by an officer of Licensee (or the officer’s designee). With each such report submitted, Licensee shall pay to Licensor the royalties and fees due and payable under this
Agreement. If no royalties shall be due, Licensee shall so report. Licensee’s failure to submit a royalty report in the required form will constitute a breach of this Agreement. Prior to achievement of Net Sales, no report shall be due to
Licensor other than as specified in Section 8.2 or in association with a payment based on one or more developmental milestones as listed in Section 5.2. 

  
 Page 13 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	8.2	Progress Report and Commercialization Plan 

 Commencing thirty days after January 1,
2015, and thirty days after each January 1 thereafter, Licensee shall submit to Licensor a written report covering Licensee’s (and any Sublicensee’s) progress in (a) development and testing of all Licensed Products;
(b) achieving the due diligence milestones specified herein; (c) preparing, filing, and obtaining of any approvals necessary for marketing the Licensed Products; and (d) plans for the upcoming year in commercializing the Licensed
Product(s). Each report shall be in substantially similar form and contain at least the information required by Exhibit “D” attached hereto and incorporated herein by this reference. 

 

	8.3	On or before the ninetieth (90th) day following the close of Licensee’s fiscal year, Licensee shall provide Licensor with Licensee’s certified
financial statements for the preceding fiscal year including, at a minimum, a balance sheet. Provision of more than a balance sheet will be at Licensee’s sole option. 

 

	8.4	In addition to the regular reports required by Section 8.1 and 8.2, hereof, Licensee shall provide a written report to Licensor of the date of first occurrence of Net Sales in each country within sixty
(60) days of the occurrence thereof. 

 ARTICLE 9. PAYMENTS, RECORDS and AUDITS 

 

	9.1	Payments 

 Licensee shall pay all royalties accruing to Licensor in U.S. Dollars, without
deduction of exchange, collection, wiring fees, bank fees, or any other charges, within thirty (30) days following the calendar quarter in which Net Sales occur. Each payment will reference KUCTC License ID # [***]. All payments to Licensor
will be made in United States Dollars by wire transfer or check payable to the [***], and sent to: 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

Wire Transfer Information: 
 [***]

 [***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

For converting any Net Sales made in a currency other than United States Dollars, the parties will use the conversion rate published in the
Wall Street Journal/Telegraphic Transfer Selling conversion rate reported by the Sumitomo Bank, Tokyo, or other industry standard conversion rate approved in writing by Licensor for the last day of the calendar quarter for which such royalty
payment is due or, if the last day is not a business day, the closest preceding business day. 

  
 Page 14 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	9.2	Late Payments 

 In the event royalty payments or other fees are not received by Licensor
when due hereunder, Licensee shall pay to Licensor interest charges at the rate of twelve percent (12%) per annum on the total royalties or fees due for the reporting period. 

 

	9.3	Records 

 Licensee shall keep, and require its Sublicensees and Affiliates to keep,
complete, true and accurate records and books containing all particulars that may be necessary for the purpose of showing the amounts payable to Licensor hereunder. Records and books shall be kept at Licensee’s principal place of business or
the principal place of business of the appropriate division of Licensee to which this Agreement relates. 
  

	9.4	Audit 

 The books and the supporting data referred to in Section 9.3 shall be open
to inspection by Licensor or its agents, upon reasonable prior notice to Licensee, at all reasonable times for a term of five (5) years following the end of the calendar year to which they pertain, upon reasonable prior notice to Licensee, for
the purpose of verifying Licensee’s royalty statement or compliance in other respects with this Agreement. Such access will be available to Licensor upon not less than ten (10) days written notice to Licensee, not more than once each
calendar year until termination of this Agreement, during normal business hours, and once a year for three (3) years after the expiration or termination of this Agreement. Should such inspection lead to the discovery of a discrepancy in
reporting to Licensor’s detriment exceeding [***] percent ([***]%) of the amount due or [***] dollar ($[***]) US, whichever is greater, Licensee agrees to pay the full cost of such inspection and shall pay such cost within thirty (30) days
after receiving written notice that such inspection showed such underpayment. If the audit determines that there has been an overpayment by Licensee, the amount of the overpayment will be deducted from the next payment due to Licensor. 

ARTICLE 10. PATENT MARKING 

Licensee shall permanently and legibly mark all Licensed Products made, used or sold under the terms of this Agreement, or their containers,
in accordance with all applicable patent-marking and notice provisions under Title 35, United States Code. 
 ARTICLE 11. PATENT
PROSECUTION AND MAINTENANCE 
  

	11.1	Future Patent Expenses 

 Licensee will pay, within thirty (30) days of invoice, all
future expenses for filing, prosecuting, enforcing, and maintaining the Patent Rights that are licensed to Licensee hereunder, including without limitation, any taxes on such Patent Rights. Licensee will receive such invoices directly from patent
counsel; Licensor will receive a copy of such invoice. Licensee shall pay such invoices directly to patent counsel with written confirmation of payment to Licensor. 
  

	11.2	Patent Counsel 

 Licensor will work closely with Licensee to develop a suitable strategy
for the prosecution and maintenance of all Patents Rights. Licensee may select patent counsel for the prosecution and maintenance of Patent Rights, provided such counsel is reasonably acceptable to Licensor. The selected patent attorney will agree
to keep both Licensee and Licensor, as co-clients, equally informed and involved as to all material information, material communications with governmental patent offices, material issues and decisions, and related matters applicable to prosecuting
the patent applications for the 

  
 Page 15 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 
Patent Rights and for maintaining the Patent Rights in good standing. Decisions for prosecuting the patent applications will be made so as to obtain the broadest patent protection that is
reasonable and practical under the circumstances. Licensee will request that copies of all documents prepared by the patent attorney selected by Licensee be provided to Licensor for review and comment prior to filing to the extent practicable under
the circumstances. All patent applications and patents will be in the name of Licensor, owned by Licensor and included as part of the Patent Rights licensed pursuant to this Agreement. Licensee will promptly notify Licensor of its plans to file,
revise or drop any patent application or claim which may adversely affect the Patent Rights or the rights or royalties of Licensor in the Licensed Product(s) under this Agreement. Licensee and the selected patent attorney shall not change any
inventorship designations and shall not drop or reduce any claim in a pending patent application which may adversely affect the Patent Rights or royalties of Licensor without the written consent of Licensor. Licensee shall notify Licensor at least
forty five (45) days prior to abandonment of any patent application and/or patents under Patent Rights. 
 ARTICLE 12. TERMINATION
BY LICENSOR 
  

	12.1	If Licensee should: (a) fail to deliver to Licensor any statement or report required hereunder when due; (b) fail to make any payment at the time that the same should be due; (c) violate or fail to
perform any covenant, condition, or undertaking of this Agreement to be performed by it hereunder; (d) cease active Commercially Reasonable Effort to commercialize a Licensed Product(s); (e) file a bankruptcy action, or have a bankruptcy
action against it, or become Insolvent; or (f) enter into a composition with creditors, or have a receiver appointed for it; then Licensor may give written notice of such default to Licensee. If Licensee should fail to cure such default within
thirty (30) days of such notice, the rights, privileges, and license granted hereunder shall automatically terminate. 

  

	12.2	No termination of this Agreement by Licensor shall relieve Licensee of its obligation to pay any monetary obligation due or owing at the time of such termination and shall not impair any accrued right of Licensor.
Licensee shall pay all attorneys’ fees and costs incurred by Licensor in enforcing any obligation of Licensee or accrued right of Licensor. Articles 7, 9, 20, 22, 25, 26, and Section 12.2, 15.2, 15.3, and 27.7 hereof shall survive any
termination of this Agreement. 

 ARTICLE 13. TERMINATION BY LICENSEE 

 

	13.1	Licensee may terminate this Agreement, in whole or as to any specified patent, at any time and from time to time without cause, by giving written notice thereof to Licensor. Such termination shall be effective one
hundred twenty (90) days after such notice and all Licensee’s rights associated therewith shall cease as of that date. 

  

	13.2	Any termination pursuant to Section 13.1 hereof shall not relieve Licensee of any obligation or liability accrued hereunder prior to the effective date of such termination, or rescind or give rise to any right to
rescind any payments made or other consideration given to Licensor hereunder prior to the time such termination becomes effective. Such termination shall not affect in any manner any rights of Licensor arising under this Agreement prior to the date
of such termination. 

 ARTICLE 14. DISPOSITION OF LICENSED PRODUCTS ON HAND 

Upon termination of this Agreement by either party pursuant to section 13.1 or 12.1, Licensee shall provide Licensor with a written inventory
of all Licensed Products in process of manufacture, in use or in stock. Licensee may dispose of any such Licensed Products within the ninety (90) day period following such termination, provided, however, that Licensee shall pay royalties and
render reports to Licensor thereon in the manner specified herein. 

  
 Page 16 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 ARTICLE 15. WARRANTY BY LICENSOR 

 

	15.1	Licensor warrants that it has the lawful right to grant the license set forth in this Agreement. 

 15.2
EXCEPT AS EXPRESSLY PROVIDED IN SECTION 15.1, THE PARTIES ACKNOWLEDGE AND AGREE THAT KU, LICENSOR, ITS AFFILIATES, AGENTS, EMPLOYEES, AND THE INVENTORS HAVE MADE NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO,
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE, OR THE VALIDITY OR ENFORCEABILITY OF PATENT RIGHTS IN NO EVENT SHALL LICENSOR, ITS AFFILIATES, AGENTS, EMPLOYEES, AND
THE INVENTORS BE HELD RESPONSIBLE FOR ANY DIRECT, SPECIAL, INDIRECT OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN CONNECTION WITH THE EXERCISE OF PATENT RIGHTS, EVEN IF LICENSOR IS ADVISED IN ADVANCE OF THE POSSIBILITY OF SUCH DAMAGES. 

 

	15.3	Nothing in this Agreement shall be construed as: 

  

	 	a.	a warranty or representation by Licensor as to the validity, enforceability, or scope of any Patent Rights. 

  

	 	b.	a warranty or representation by Licensor that the exercise or practice by the Licensee of the license granted herein (including making, using, selling, offering for sale, or importing the Licensed Product) is or will be
free from infringement of intellectual property rights of third parties. 

  

	 	c.	an obligation by Licensor or KU to bring or prosecute actions or suits against third parties for patent infringement, except as expressly provided in Article 16 hereof. 

 

	 	d.	an obligation to furnish any know-how not provided in the Patent Rights. 

  

	 	e.	conferring by implication, estoppel or otherwise any license or rights under any patents of Licensor other than Patent Rights. 

  

	15.4	Any breach of the representations or warranties made in this Article 15 shall entitle Licensee to a refund of all payments made to Licensor as consideration for the rights granted under this Agreement, and said refund
shall be the sole remedy available to Licensee for breach or violation of any provisions contained in this Article 15. 

ARTICLE 16. INFRINGEMENT 
  

	16.1	If either party learns of a claim of infringement of any of Licensor’s Patent Rights licensed under this Agreement, that party shall give written notice of such claim to the other party. Licensor, in consultation
with Licensee, shall then use reasonable efforts to terminate such infringement if the parties mutually agree that such efforts are appropriate under the circumstances. In the event Licensor fails to abate the infringing activity within ninety
(90) days after such written notice or to bring legal action against the third party, Licensee may bring suit for patent infringement. No settlement, consent judgment or other voluntary final disposition of the suit may be entered into without
the consent of Licensor, which consent shall not be unreasonably withheld. 

  

	16.2	Any such legal action shall be at the expense of the party by whom suit is filed, hereinafter referred to as the “Litigating Party”. Any damages or costs recovered by the Litigating Party in connection with a
legal action filed by it hereunder, and provided that the Litigating Party is reimbursed for its costs and expenses reasonably incurred in the lawsuit, and after any royalties or other payments due to Licensor under Article 4 are paid, shall be
retained by Licensee under the following conditions: (a) damages for lost sales shall be treated as Net Sales (after reasonable costs and expenses of litigation are subtracted), and the royalty due on the corresponding amount of Net Sales shall
be paid to Licensor; (b) [***] percent ([***]%) of punitive damages, if any, in excess of damages for lost sales shall be paid to Licensor and the remainder shall be retained by Licensee. 

  
 Page 17 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	16.3	Licensee and Licensor shall cooperate with each other in litigation proceedings instituted hereunder, provided that such cooperation shall be at the expense of the Litigating Party, and such litigation shall be
controlled by the Litigating Party. 

 ARTICLE 17. INSURANCE 

 

	17.1	Insurance Requirements 

 Beginning at the time any Licensed Product is being distributed
or sold (including for the purpose of obtaining any required regulatory approvals) by Licensee, Affiliate, or a Sublicensee, Licensee will, at its sole cost and expense, procure and maintain commercial general liability insurance issued by an
insurance carrier with an A.M. Best rating of “A” or better in amounts not less than $[***] per incident and $[***] annual aggregate. Licensee will have Licensor, KU, and their respective officers, employees and agents, named as additional
insureds. All rights of subrogation will be waived against Licensor and its insurers. Such commercial general liability insurance will provide (i) product liability coverage; (ii) broad form contractual liability coverage for
Licensee’s indemnification under this Agreement; and (iii) coverage for litigation costs. The specified minimum insurance amounts will not constitute a limitation on Licensee’s obligation to indemnify Licensor, KU, and their
respective officers, employees and agents, under this Agreement. 
  

	17.2	Evidence of Insurance and Notice of Changes 

 Licensee will provide Licensor with written
evidence of such insurance upon request by Licensor. Licensee will provide Licensor with written notice of at least thirty (30) days prior to the cancellation, non-renewal, or material change in such insurance. 

 

	17.3	Continuing Insurance Obligations 

 Licensee will maintain such commercial general
liability insurance beyond the expiration or termination of this Agreement during (i) the period that any Licensed Product(s) and/or Licensed Service(s) developed pursuant to this Agreement is being commercially distributed or sold by Licensee,
any Affiliate, or any Sublicensee or agent of Licensee; and (ii) for five (5) years after such period. 
 ARTICLE 18. WAIVER

 No waiver by either party hereto of any breach or default of any of the covenants or agreements herein set forth shall be deemed
a waiver as to any subsequent and/or similar breach or default. 
 ARTICLE 19. ASSIGNABILITY 

This Agreement is not assignable or otherwise transferable by Licensee without the prior written consent of Licensor, except in conjunction
with a merger, acquisition, or similar transaction. The failure of Licensee to comply with the terms of this paragraph shall be grounds for termination of the Agreement by Licensor under Article 12. 

  
 Page 18 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 ARTICLE 20. INDEMNIFICATION BY LICENSEE 

Licensee shall indemnify, hold harmless and defend Licensor, KU, and their respective officers, employees, inventors, affiliates, and agents,
against any and all claims, suits, losses, damages, costs, liabilities, fees and expenses (including reasonable fees of attorneys) resulting from or arising out of or in connection with: (a) the exercise of any license granted under this
Agreement; (b) the breach of this Agreement by Licensee; (c) Licensee’s failure to comply with any applicable laws, rules, or regulations, or (d) any act, error, or omission of Licensee, its officers, agents, employees,
Affiliates, or Sublicensees, except where such claims, suits, losses, damages, costs, fees, or expenses result solely from the gross negligence, fraud, or intentional misconduct of the Licensor, its affiliates, officers, employees or agents.
Licensee shall give Licensor prompt and timely notice of any claim or suit instituted of which Licensee has knowledge that in any way, directly or indirectly, affects or might affect Licensor, and Licensor shall have the right at its own expense to
participate in the defense of the same. 
 ARTICLE 21. NOTICES 

Any payment, notice or other communication required or permitted to be given to either party hereto shall be in writing and shall be deemed to
have been properly given and effective: (a) on the date of delivery if delivered in person during recipient’s normal business hours; or (b) on the date of attempted delivery if delivered by courier, express mail service or first-class
mail, registered or certified. Such notice shall be sent or delivered to the respective addresses given below, or to such other address as either party shall designate by written notice given to the other party as follows: 

In the case of Licensee: 
 Reata
Pharmaceuticals, Inc. 
 Attn: Robin Kral, VP of Licensing & Intellectual Property 

2801 Gateway Drive, Suite 150 

Irving, Texas 75063 
 In the case
of Licensor: 
 KU Center for Technology Commercialization, Inc. 

Attn: Director, KUCTC 
 KU Medical
Center 
 Wescoe Pavilion M.S. 1039 

3901 Rainbow Boulevard 
 Kansas
City, Kansas 66160 
 ARTICLE 22. REGULATORY COMPLIANCE 

 

	21.1	When required by local/national law, Licensee shall register this Agreement, pay all costs and legal fees connected therewith, and otherwise ensure that the local/national laws affecting this Agreement are fully
satisfied. 

  

	21.2	 Licensee shall comply with all applicable U.S. laws dealing with the export and/or management of technology or information. Licensee understands that
the Arms Export Control Act (AECA), including its implementing International Traffic In Arms Regulations (ITAR,) and the Export Administration Act (EAA), including its Export Administration Regulations (EAR), are some (but not all) of the laws and
regulations that comprise the U.S. export laws and regulations. Licensee further understands that the U.S. export laws and regulations include (but are not limited to): (1) ITAR and EAR product/service/data-specific requirements; (2) ITAR
and EAR ultimate destination-specific requirements; (3) ITAR and EAR end user-specific requirements; (4) ITAR and EAR end use-specific requirements; (5) Foreign Corrupt Practices Act; and (6) anti-boycott laws and regulations.
Licensee will comply with all then-current applicable export laws and regulations of the U.S. Government (and other applicable U.S. laws and regulations) pertaining to the Licensed Product(s) (including any associated products, items, articles,
computer software, media, services, technical data, and other information). Licensee certifies that it will not, directly or indirectly, export (including any deemed export), nor 

  
 Page 19 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	 	
re-export (including any deemed re-export) the Licensed Product(s) (including any associated products, items, articles, computer software, media, services, technical data, and other information)
in violation of U.S. export laws and regulations or other applicable U.S. laws and regulations. Licensee will include an appropriate provision in its agreements with its authorized Sublicensees to assure that these parties comply with all
then-current applicable U.S. export laws and regulations and other applicable U.S. laws and regulations 

  

	21.3	Licensee agrees to use commercially reasonable efforts to ensure that products used or sold in the United States embodying Licensed Products shall be manufactured substantially in the United States, unless a written
waiver is obtained in advance from the sponsoring federal agency. 

 ARTICLE 23. GOVERNING LAW 

This Agreement shall be interpreted and construed in accordance with the laws of the State of Kansas, without application of any principles of
choice of laws. 
 ARTICLE 24. RELATIONSHIP OF PARTIES 

In assuming and performing the respective obligations under this Agreement, Licensee and Licensor are each acting as independent parties and
neither shall be considered or represent itself as a joint venture, partner, agent or employee of the other. 
 ARTICLE 25. USE OF
NAMES 
  

	25.1	By Licensee 

 Licensee shall not, without prior written consent of the Licensor, use the
name or any trademark or trade name owned by Licensor, KU, or by an affiliate of KU, in any publication, publicity, advertising, or otherwise, except that Licensee may identify KUCTC as licensor of the Patent Rights and Licensed Products. 

 

	25.2	By Licensor 

 Licensor may use Licensee’s name in connection with Licensor’s
publicity related to Licensor’s intellectual property and commercialization achievements. 
 ARTICLE 26. DISPUTE RESOLUTION

 Except for the right of either party to apply to a court of competent jurisdiction for a temporary restraining order, a
preliminary injunction, or other equitable relief to preserve the status quo or prevent irreparable harm, any and all claims, disputes or controversies arising under, out of, or in connection with the Agreement, including but not limited to any
dispute relating to patent validity or infringement, which the parties shall be unable to resolve within sixty (60) days shall be mediated in good faith. The party raising such dispute shall promptly advise the other party, in writing, of such
dispute. By not later than five (5) business days after the recipient has received such notice of dispute, each party shall have selected for itself a representative who shall have the authority to bind such party, and shall additionally have
advised the other party in writing of the name and title of such representative. By not later than ten (10) days after the date of such notice of dispute, the party against whom the dispute shall be raised shall select a mediator in the Kansas
City area and such representatives shall schedule a date with such mediator for a hearing. The parties shall enter into good faith mediation and shall share the costs equally. If the representatives of the parties have not been able to resolve the
dispute within fifteen (15) business days after such mediation hearing, then any and all claims, disputes or controversies arising under, out of, or in connection with this Agreement, including any dispute relating to patent

  
 Page 20 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 
validity or infringement, shall be resolved through arbitration if the parties mutually consent, or through any judicial proceeding either in the courts of the State of Kansas or in the United
States District Court for the District of Kansas, to whose jurisdiction for such purposes Licensee and Licensor each hereby irrevocably consents and submits. All costs and expenses, including reasonable attorneys’ fees, of the prevailing party
in connection with resolution of a dispute by arbitration or litigation of such controversy or claim shall be borne by the other party. 

ARTICLE 27. GENERAL PROVISIONS 
  

	27.1	The headings of the several sections are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. 

 

	27.2	This Agreement shall not be binding upon the parties until it has been signed below by or on behalf of each party. 

  

	27.3	No amendment or modification of this Agreement shall be valid or binding upon the parties unless made in writing and signed by both parties hereto. 

 

	27.4	This Agreement embodies the entire understanding of the parties and supersedes all previous communications, representations or understandings, either oral or written, between the parties relating to the subject matter
thereof. 

  

	27.5	The provisions of this Agreement are severable, and in the event that any provision of this Agreement shall be determined to be invalid or unenforceable under any controlling body of the law, such invalidity or
unenforceability shall not in any way affect the validity or enforceability of the remaining provisions hereof. 

  

	27.6	This Agreement may be signed in counterparts, each of which when taken together shall constitute one fully executed document. Each individual executing this Agreement on behalf of a legal Entity does hereby represent
and warrant to each other person so signing that he or she has been duly authorized to execute this Agreement on behalf of such Entity. 

  

	27.7	In the event of any litigation, arbitration, judicial reference or other legal proceeding involving the parties to this Agreement to enforce any provision of this Agreement, to enforce any remedy available upon default
under this Agreement, or seeking a declaration of the rights of either party under this Agreement, the prevailing party shall be entitled to recover from the other such attorneys’ fees and costs as may be reasonably incurred, including the
costs of reasonable investigation, preparation and professional or expert consultation incurred by reason of such litigation, arbitration, judicial reference, or other legal proceeding. 

 

	27.8	Except as required by law, neither party may disclose the financial terms of this Agreement without the prior written consent of the other party. 

  
 Page 21 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 IN WITNESS WHEREOF, Licensor and Licensee have executed this Agreement by their respective officers hereunto
duly authorized, on the day and year hereinafter written. 
  

									
	“Licensee”	 		 	“Licensor”
			
	REATA PHARMACEUTICALS, INC.	 		 	KU CENTER FOR TECHNOLOGY COMMERCIALIZATION, INC.
					
	By	 	 /s/ J. Warren Huff
	 		 	By	 	 /s/ Rajiv Kulkarni, Ph.D, MBA, CLP

		 	(Signature)	 		 		 	(Signature)
	Name	 	J. Warren Huff	 		 	Name:	 	Rajiv Kulkarni, Ph.D, MBA, CLP
		 	(Please Print)	 		 		 	
	Title	 	Chief Executive Officer	 		 	Title:	 	Director
					
	Date	 	9/29/2014	 		 	Date	 	9/30/2014

  
 Page 22 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 EXHIBIT “A” 

PATENT RIGHTS 

  
 Page 23 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

									
	 KU Ref No.
	  	 Matter
	  	Application No.
Date of Filing	  	Title	  	Inventor(s)
					
	 [***]
	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	 [***]
	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	 [***]
	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	 [***]
	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	 [***]
	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	 [***]
	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	 [***]
	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	 [***]
	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	 [***]
	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	 [***]
	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	 [***]
	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	 [***]
	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	 [***]
	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]

  
 Page 24 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 EXHIBIT “B” 

LICENSE TO THE UNITED STATES GOVERNMENT 

This instrument confers to the United States Government, as represented by the Department of Health and Human Services, a non-exclusive, non-transferable,
irrevocable, paid-up license to practice or have practiced on its behalf throughout the world the following subject inventions. This license will extend to all divisions or continuations of the patent application and all patents or reissues, which
may be granted thereon: 
 Invention Title: 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

[***]. 
 Inventor(s): 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

Patent Application Serial No.: All Patent Application Serial numbers in Exhibit A including foreign patent applications. 

The subject Inventions were conceived and/or first actually reduced to practice in performance of a government-funded project, Grant Nos.: [***],
[***],[***],[***] and [***],[***],[***],[***],[***], and [***]. 
 Principal rights to this subject invention have been left with the University of Kansas,
subject to the provisions of 37 CFR 401 and 45 CFR 8. 
  

									
	Signed:	 	  
	 		 	Date:	 	  

	Name:	 	Rajiv Kulkarni, Ph.D, MBA, CLP	 		 	Title:	 	Director, KUCTC

  
 Page 25 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 EXHIBIT “C” 

2015 ROYALTY REPORT 
  

			
	LICENSEE:                                    
                                         
   	  	KUCTC Technology ID #                             
		
	Period Covered:
From                      Through:                
       	  	
		
	Prepared By:
                                         
                                     	  	Date:                         
		
	Approved By:
                                         
                                   	  	Date:                         

 If Licensee has several licensed products, please prepare separate reports for each. Then, compile all licensed products into
a summary report. 
  

																													
	Country and	  	Product or	  	Quantity	  	Unit	  	Gross	 	  	* Less	 	  	Net	 	  	Royalty	  	Period Royalty Amount	 
	 Patent
	  	Tradename	  	Sold	  	Price	  	Sales	 	  	Allowances	 	  	Sales	 	  	Rate	  	This Year	 	  	Last Year	 
	USA	  		  		  		  	 	$	  	  	 	$	  	  	 	$	  	  		  	 	$	  	  	 	$	  
	#	  		  		  		  				  				  				  		  				  			
	Canada	  		  		  		  				  				  				  		  				  			
	#	  		  		  		  				  				  				  		  				  			
	Europe:	  		  		  		  				  				  				  		  				  			
	#	  		  		  		  				  				  				  		  				  			
	#	  		  		  		  				  				  				  		  				  			
	#	  		  		  		  				  				  				  		  				  			
	#	  		  		  		  				  				  				  		  				  			
	#	  		  		  		  				  				  				  		  				  			
	#	  		  		  		  				  				  				  		  				  			
	Japan	  		  		  		  				  				  				  		  				  			
	#	  		  		  		  				  				  				  		  				  			
	Other:	  		  		  		  				  				  				  		  				  			
	#	  		  		  		  				  				  				  		  				  			
	#	  		  		  		  				  				  				  		  				  			
	Sublicense #1 (name)	  		  		  		  				  				  				  		  				  			
	#	  		  		  		  				  				  				  		  				  			
	 Sublicense #2
 (name)
	  		  		  		  				  				  				  		  				  			
	#	  		  		  		  				  				  				  		  				  			
		  	  
	  	  
	  	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  	  
	  
	 	  	  
	  
	 
	 TOTAL:
	  		  		  		  	$	 	  	  	$	 	  	  	$	 	  	  		  	$	 	  	  	$	 	  
		  	  
	  	  
	  	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  	  
	  
	 	  	  
	  
	 

 Total Royalty Due:
$                                         
            
 Sales Milestone Payments: If any of the cumulative sales milestones in
Section 5.3 of the Exclusive License Agreement have been achieved, specify the milestone(s) achieved and the associated payment(s) due. If payment has not already been made in accordance with Section 5.3, please include such payment
separately along with the total royalty due. 

  
 Page 26 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	*	On a separate page, please indicate the reasons for adjustments, if significant. Please refer to the following examples as applicable: (1) cash, trade or quantity discounts actually allowed; (2) sales, use,
tariff, customs duties or other excise taxes directly imposed upon particular sales; (3) outbound transportation charges—prepaid or allowed, and (4) allowances or credits to third parties for rejections or returns. 

  
 Page 27 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 EXHIBIT “D” 

ANNUAL DEVELOPMENT AND COMMERCIALIZATION REPORT 

For 
 Reata Pharmaceuticals,
Inc. 
 [***] (if several, use oldest) 

For period beginning
                                 and ending
                         (“Period”) 

Date:
                                     

Contact Person:
                                 Phone:
                             Email:
                                        

  

	1.	Commercialization Efforts 

  

	 	A.	List all countries in which marketing approval was first received for a Licensed Product in the preceding calendar year. Provide the corresponding commercial name of any such newly approved Licensed Products.

  

	 	B.	List all countries in which an NDA or equivalent marketing application was filed for a Licensed Product in the preceding calendar year, providing details of the applicable indication(s). If any such application was not
accepted, or if the application was not approved, provide details. 

  

	 	C.	List all countries in which first commercial sales of a Licensed Product were achieved in the preceding calendar year. 

  

	 	D.	List any other material changes in the marketing status of any Licensed Product. 

  

	 	E.	If any of A-C above is associated with a milestone payment under Section 5 of the Exclusive License Agreement, please note this and confirm that the payment has been made. 

 

			
	     Yes      No	  	In the designated reporting period, did your company or any Sublicensee of the above-referenced technology have 500 or more employees? (This information is required to determine and report large or small entity status in the
United States.)

  

	2.	Product Development 

  

	 	A.	List all clinical trials of Licensed Products that were initiated in the preceding calendar year, whether by Licensee or a Sublicensee. 

 

	 	B.	List all clinical trials of Licensed Products that were completed in the preceding calendar year. If the results are known and have been publicly disclosed, provide a summary of the results (if a press release or other
public disclosure concerning such results became available during the preceding calendar year, please provide if not previously communicated to Licensor). If a trial was initiated but not completed, describe the trial and the reasons for
non-completion. 

  
 Page 28 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	 	C.	If a Licensed Product has not yet entered clinical trials, list all major non-clinical studies completed during the preceding calendar year (i.e., GLP studies designed to support an IND or NDA filing) and provide a
summary of the results if known. 

  

	 	D.	List any significant manufacturing issues or achievements related to Licensed Products during the preceding calendar year. 

  
 Page 29 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 EXHIBIT “E” 

CURRENT DEVELOPMENT PLAN 

[***] Program 
 [***] 

Exhibit “E” 
 CURRENT DEVELOPMENT PLAN 

In addition to the activities shown above, manufacturing studies will address the feasibility of large-scale production of both [***] and [***]. Research at KU
sponsored by Licensee will support in vivo testing of these compounds, and others, in models of diabetic neuropathy. Studies with anti-cancer compounds will be directed towards further profiling and eventual selection of a lead compound for detailed
in vivo profiling. 

  
 Page 30 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 EXHIBIT “F” 

MATERIAL TRANSFER AGREEMENT TEMPLATE 
 THIS
AGREEMENT, between                     having an address at
                    , hereinafter referred to as “RECIPIENT,” and the University of Kansas, having an address at Youngberg Hall, 2385
Irving Hill Road, Lawrence, KS 66045-7568, hereinafter referred to as “UNIVERSITY,” shall govern the conditions of disclosure by UNIVERSITY to RECIPIENT of certain confidential information (DATA) and/or materials (MATERIALS) listed in
Exhibit “A” relating to                     . MATERIALS, as used herein, include all such original materials actually provided to
RECIPIENT, plus any materials derived by RECIPIENT directly therefrom. 
 IN CONSIDERATION of the transfer of MATERIALS and/or disclosure of DATA, and the
mutual promises set forth in this Agreement, the parties intending to be legally bound and agree as follows: 
  

	 	1.	The Principal Investigator from RECIPIENT,                     , will receive the MATERIALS and/or DATA and is also
bound by the conditions of this Agreement. 

  

	 	2.	RECIPIENT hereby agrees: 

  

	 	a.	Not to use such MATERIALS or DATA for any commercial purpose, and limit use of DATA and MATERIALS only to the non-commercial research purpose described in Exhibit X (the “Research Plan”). Recipient agrees not
to analyze, have analyzed or otherwise attempt to ascertain the chemical composition, functional mechanisms, nor physical structure of said proprietary samples or MATERIAL outside the scope of the Purpose without the prior written consent of
UNIVERSITY. MATERIAL shall not be used for any purpose other than performance of the Research Plan, and shall not be used in humans under any circumstances. 

  

	 	b.	Except as provided in (c) below, not to disclose DATA to others (except to its employees who reasonably require same for the purposes hereof and who are bound to it by like obligation as to confidentiality) without
the express written permission of UNIVERSITY. 

  

	 	c.	RECIPIENT shall not be prevented from using or disclosing DATA: 

  

	 	i.	which RECIPIENT can demonstrate by written records was previously known to it; 

  

	 	ii.	which is now, or becomes in the future, public knowledge other than through acts or omissions of RECIPIENT; 

  

	 	iii.	which is independently developed by RECIPIENT by those not having access to the DATA and which can be proven through verifiable written records; or 

 

	 	iv.	which is lawfully obtained by RECIPIENT from sources independent of UNIVERSITY without any obligation of confidentiality to the UNIVERSITY; or 

 

	 	v.	to the extent such use or disclosure is required by law or by court order, providing such use and disclosure is limited to such purpose. 

 

	 	d.	To provide UNIVERSITY with a copy of information generated using DATA and/or MATERIALS. 

  

	 	e.	Not to transfer MATERIALS to any others (except to its employees who are bound to RECIPIENT by like obligations conditioning and restricting access, use, and continued use of MATERIALS) without the express written
consent of UNIVERSITY. 

  

	 	f.	To safeguard MATERIALS and/or DATA against disclosure and transmission to others with the same degree of care as it exercises with its own materials of a similar nature, but in no case less than a reasonable degree of
care. 

  

	 	g.	To return all MATERIALS and DATA within Fifteen (15) days of the expiration date of this Agreement, unless this deadline is extended by UNIVERSITY in writing before said Fifteen (15) days has elapsed.

  
 Page 31 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	 	h.	To the extent permitted by law, to hold harmless UNIVERSITY against any claims, costs, or other liabilities which may arise as a result of: 1) RECIPIENT’S storage, use or disposal of MATERIAL or use of DATA; and 2)
RECIPIENT’S breach of this Agreement. RECIPIENT assumes all liability for damages which may arise from its use, storage or disposal of MATERIAL. 

  

	 	i.	The RECIPIENT agrees to use the MATERIAL and/or DATA in compliance with all applicable statutes and regulations, including Public Health Service and National Institutes of Health regulations and guidelines such as, for
example, those relating to research involving the use of animals or recombinant DNA. 

  

	 	j.	Recipient shall observe all applicable laws with respect to the transfer of the MATERIAL and related technical data to foreign countries, including without limitation, the International Traffic in Arms Regulations
(ITAR) and the Export Administration Regulations. 

  

	 	k.	With regard to any publications resulting from the use of DATA or MATERIALS, to include appropriate UNIVERSITY authors, where applicable, and submit to the UNIVERSITY any publications for review by UNIVERSITY ninety
(90) days prior to submission in order to file a patent application or take such other measures as UNIVERSITY deems necessary to establish and preserve its proprietary rights. 

 

	 	3.	UNIVERSITY MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF
MATERIALS, DATA OR INFORMATION WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS. 

  

	 	4.	Title and all rights to DATA and MATERIALS provided under this Agreement shall remain vested in UNIVERSITY. It is further agreed that the furnishing of DATA or MATERIALS to RECIPIENT shall not constitute any express or
implied grant or license to RECIPIENT under any patents, patent application, trade secrets or other proprietary or legal rights now or hereinafter held by UNIVERSITY. RECIPIENT acknowledges that MATERIALS are the subject of an Exclusive License
Agreement between UNIVERSITY and its Licensee. If any invention arises from RECIPIENT’s use of MATERIALS, or derived from MATERIALS, RECIPIENT is free to file patent application(s) claiming such invention, but agrees to promptly notify
UNIVERSITY upon filing a patent application. RECIPIENT shall allow UNIVERSITY’s Licensee to enter into confidential, good faith negotiations for a license to such invention and any related patents that claim priority to such invention.
RECIPIENT hereby grants to UNIVERSITY a non-exclusive, royalty-free, transferrable license, to make and use any such invention(s) derived from Recipient’s use of the MATERIAL for non-commercial research purposes. 

 

	 	5.	RECIPIENT’s right to use the DATA and/or MATERIALS shall expire one (1) year from the date of RECIPIENT’s signature below. At the end of that period, RECIPIENT will either enter into good faith
negotiations with UNIVERSITY for a commercial license should one still be available at that time, or else return MATERIAL within fifteen (15) days. 

  

	 	6.	This AGREEMENT may be terminated by either party on thirty (30) days written notice to the other party. RECIPIENT’s obligations under section 1, 2(a), 2(b), and 2(d) through (k), and 4 shall survive
termination of the Agreement. 

  

	 	7.	The interpretation and validity of this AGREEMENT and the rights of the parties shall be governed by the laws of the State of Kansas. The Federal and State courts located in Kansas shall have sole and exclusive
jurisdiction over any disputes arising under the terms of this Agreement. 

  

	 	8.	This AGREEMENT may not be modified except by written instrument signed on behalf of each party. This AGREEMENT embodies the entire agreement and understanding of the parties and terminates and supersedes all prior
independent agreements and under takings between the parties. 

  
 Page 32 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

			
	Recipient	  	The University of Kansas
		
	
By:                         
                                

(Signature)
	  	
By:                         
                                

(Signature)

		
	Name:	  	Name: Joseph A. Heppert, Ph.D.
		
	Title:	  	Title: Associate Vice Chancellor for Research
		
	Date:                                     
                	  	Date:                                     
                
		
	
By:                         
                                

(Signature)
	  	
By:                         
                                

(Signature)

		
	Name:	  	Name:
		
	Title:	  	Title:
		
	Date:                                     
                	  	Date:                                     
                
		
	Recipient Scientist	  	

  

	
	I,             have read the provisions of this agreement and agree to abide by and am bound by all conditions of this Agreement.

  

	
	
By:                         
                    
 (Signature)

	
	
Name:                         
               
 (Please Print)

	
	Title:
                                         
 
	
	Date:
                                         

  
 Page 33 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 Research plan of MTA Template in Exhibit F 

  
 Page 34 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}]]